Author: Ravi Shankar

EINDHOVEN, The Netherlands, Oct. 27, 2026 (GLOBE NEWSWIRE) — ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announced that it will release its third-quarter 2026 financial results and host a webcast with a comprehensive business update on November 3, 2026.

The webcast, presented by CEO Dave Marver, will begin at 2:00 p.m. CET / 8:00 a.m. ET. To join, please register using this link. A replay of the webcast and supporting materials will be available at ir.onwd.com.

About ONWARD Medical

ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities. Building on decades of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company developed its proprietary ARC Therapy. It has subsequently been awarded 10 Breakthrough Device Designations from the FDA. The Company’s ARC-EX^® System is cleared for commercial sale in the US and Europe. The Company is also developing an investigational implantable system called ARC-IM^®, designed to address several unmet needs including blood pressure instability after spinal cord injury. It can also be paired with a brain-computer interface (BCI) and artificial intelligence (AI) to restore thought-driven movement.

Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD), and its US ADRs can be traded on OTCQX (ticker: ONWRY).

To learn more about ONWARD Medical’s commitment to partnering with the spinal cord injury community to develop innovative solutions for restoring movement, function, and independence after spinal cord injury, please visit ONWD.com.

To be kept informed about the Company’s technologies, research studies, and the availability of therapies in your area, please complete this webform.

For Media Inquiries:
Sébastien Cros, VP Communications
media@onwd.com

For Investor Inquiries:
investors@onwd.com

Disclaimer

Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Trademarks: ONWARD, ARC-EX, ARC-IM, ARC-BCI, and the stylized O-Logo are proprietary and registered trademarks of ONWARD Medical. Unauthorized use is strictly prohibited.

Investigational Products: ARC-IM and ARC-BCI are investigational and not available for commercial use. ARC-IM is limited by United States law to investigational use.

Paris, France – October 27, 2026

Q3 2026 financial results and conference call

Viridien will publish its third quarter 2026 results on Tuesday, November 3, after market close.

• The press release and presentation will be made available on www.viridiengroup.com at 5.45 pm (CET)
• An English-language conference call is scheduled at 6.00 pm (CET) on the same day

Participants must register for the conference call by clicking here to receive a dial-in number and PIN code. Participants may also join the live webcast by clicking here.

A replay of the conference call will also be available, for a period of 12 months, on the Company’s website www.viridiengroup.com.

About Viridien:

Viridien (www.viridiengroup.com) is an advanced technology, digital and Earth data company that pushes the boundaries of science for a more prosperous and sustainable future. With our ingenuity, drive and deep curiosity we discover new insights, innovations, and solutions that efficiently and responsibly resolve complex natural resource, digital, energy transition and infrastructure challenges. Viridien employs around 3,000 people worldwide and is listed as VIRI on the Euronext Paris SA (ISIN: FR001400PVN6).

Contacts

Investor Relations Alexandre Leroy Tel: + 33 6 85 18 44 31 E-Mail: ir@viridengroup.com

Media Relations Sara Pink-Zerling Tel: + 33 6 37 57 95 44 E-Mail: media.relations@viridiengroup.com

Attachment

• Publication of the Q3 2026 financial results on Tuesday November 3, 2026, after market close

Press release
Paris, 27 October 2026

Financial information at September 30, 2026

Orange maintains solid revenue growth in the third quarter and raises its full-year EBITDAaL growth target

• Revenue rose +3.6%¹ in the third quarter, driven by growth across all our geographies: Africa and Middle East (+14.2%), Europe 6² (+5.3%), Spain (+3.5%) and France (+0.5%).
• Robust retail services growth of +3.3%, supported by a strong commercial performance.
• EBITDAaL grew +4.6% (+4.8% over 9 months), enabling the Group to raise its 2026 Group EBITDAaL growth guidance to above +4.5%.
• eCAPEX decreased -2.5% in the quarter; the eCAPEX-to-revenue ratio standing at 14.8% over 9 months.
• Operating cash-flow (EBITDAaL – eCapex) significant increase by +8.8% over 9 months.

In millions of euros		3Q 2026	change comparable basis	change historical basis		9M 2026	change comparable basis	change historical basis
Revenues		12,191	3.6 %	22.0 %		33,138	3.5 %	11.0 %
EBITDAaL		4,140	4.6 %	20.4 %		10,268	4.8 %	12.7 %
eCAPEX		1,712	(2.5) %	16.7 %		4,893	0.8 %	9.0 %
EBITDAaL – eCAPEX		2,428	10.3 %	23.2 %		5,374	8.8 %	16.2 %

Note: Orange España (formerly MasOrange) was accounted for using the equity method for the first five months of 2026 and has been fully consolidated since June 2026.

“This third quarter confirms the strong momentum generated by our Trust the future plan. Revenue increased across all our geographies, driven by a robust commercial performance. Africa and Middle East continued its remarkable growth, while Europe, particularly Poland, delivered solid results.

We are continuing to implement our plan, with several developments in the third quarter: the launch of new offers in France, the integration of MasOrange now renamed Orange España, sustained growth of Orange Cyberdefense, and an extended SecNumCloud qualification for Orange Business’s cloud offerings.

In October, we signed a letter of intent with Deutsche Telekom, Telefónica and Vodafone to explore a joint bid for MSS spectrum allocation in Europe for mobile satellite services. This initiative supports the ambition to strengthen the sovereignty, security and resilience of Europe’s strategic infrastructure.

Building on sustained EBITDAaL growth of 4.8% in the first nine months of the year, we are raising our 2026 target to growth of more than 4.5%.

I would like to thank all our teams for their commitment and for driving our projects and transformation forward.”

Christel Heydemann, Orange group CEO

In the third quarter of 2026, the Group generated revenue of €12.2 billion, up 3.6%. All geographies contributed to this growth: Africa and Middle East (+14.2%), Europe 6 (+5.3%), Spain (+3.5%) and France (+0.5%). Retail services grew by +3.3%, reflecting solid commercial momentum, driven by remarkable growth in Africa and Middle East (+15.2%), the acceleration of convergent services in Europe 6 (+6.7%) and increase in retail services excluding PSTN³ in France (+1.1%).

The Group’s EBITDAaL reached €4.1 billion in the third quarter, up 4.6%, driven by accelerating revenue growth and continued operational efficiency initiatives. The strong EBITDAaL performance, with growth of 4.8% in the first nine months of the year, enables the Group to raise its 2026 growth guidance from above 4% to above 4.5%.

eCAPEX amounted to €1.7 billion in the third quarter, down 2.5%, and represented 14.8% of revenue over the first nine months of the year, well in line with the annual target of around 15%.

Operating cash-flow (EBITDAaL – eCapex) increased significantly by 10.3% in the third quarter, fueling growth to 8.8% over the first nine months of the year.

Commercial performance

The Group continues to expand its customer base, which exceeded 367 million accesses at the end of September 2026.

In thousand, at the end of the period			September 30 2026		September 30 2025 historical basis
Number of convergent customers			14 267		9 256
Number of mobile accesses (excluding MVNOs)			322 310		269 736
Number of fixed accesses			45 342		38 102
o/w	Very high‑speed broadband fixed accesses		24 423		15 981
The 2026 data includes accesses from Orange España (formerly MasOrange), fully consolidated in the Orange Group accounts since June 2026.

Joint bid to acquire SFR alongside Bouygues Telecom and Free–iliad Group
        
On 6 June 2026, Orange, alongside Bouygues Telecom and Free–iliad Group, announced the signature of a Memorandum of Understanding with Altice France to acquire SFR, France’s second-largest telecommunications operator.
While rulings are expected in proceedings brought by the works council within the Altice France group, Orange remains committed to constructive social dialogue, which is ongoing.
Expected closing in the second half of 2027 remains unchanged, subject to regulatory approvals.

Guidance

The Group raises its EBITDAaL target, and confirms all the other financial elements of the guidance for 2026:

• EBITDAaL growth exceeding +4.5% (previously above +4%)
• eCAPEX-to-revenue ratio of approximately 15%
• Organic cash flow⁴ reaching around €4.3 billion (target raised in Q2 2026)
• Net debt/EBITDAaL ratio with a medium-term target of around 2x

For the 2026 fiscal year, Orange has set a dividend of €0.79 per share, payable in 2027⁵.

Orange will make an interim dividend cash payment for 2026 of €0.30 per share on December 3, 2026.

___________________________________________________________________________________________

The Board of Directors of Orange SA met on 26 October 2026 and reviewed the consolidated results as of 30 September 2026.

Further information on the Group’s results and performance indicators is available on Orange’s website Financial and extra-financial information | Orange.

Review by operating segment

France

In millions of euros		3Q 2026	change comparable basis	change historical basis		9M 2026	change comparable basis	change historical basis
Revenue		4,363	0.5 %	0.5 %		13,034	1.0 %	1.0 %
Retail services (B2C+B2B)		2,822	(0.0)%	(0.0)%		8,432	0.0 %	0.0 %
Convergence		1,381	1.7 %	1.7 %		4,107	2.1 %	2.1 %
Mobile-only		558	(3.0)%	(3.0)%		1,673	(2.8)%	(2.8)%
Fixed-only		883	(0.8)%	(0.8)%		2,653	(1.2)%	(1.2)%
Wholesale		980	(4.1)%	(4.1)%		3,034	(0.4)%	(0.4)%
Equipment sales		392	16.1 %	16.1 %		1,024	9.2 %	9.2 %
Other revenue		170	6.7 %	6.7 %		545	9.8 %	9.8 %

Revenue growth driven by strong retail services momentum with record net adds

Revenue in France reached €4,363 million in the third quarter of 2026, up +0.5%. Retail services excluding PSTN continued to grow at +1.1%, supported by our effective value and multi-service strategy. Equipment sales increased +16.1%, driven by strong demand for premium devices. Wholesale services continued to decline at the expected pace (-4.1%).

In the third quarter 2026, Orange France achieved record net adds in mobile (+146k), fixed broadband (+78k) and, particularly, convergence (+57k).

Fixed-only broadband ARPO increased (+€0.4 yoy to €38.7), driven by growth in multi-service offers and upselling initiatives. Mobile-only ARPO declined (-€0.8 yoy to €15.9) due to the competitive market environment, partly reflected in convergent ARPO (-€0.3 yoy to €78.3).

Customer satisfaction and innovation remain key differentiators for Orange, which maintains its leading position in Net Promoter Score with a 9-point lead over the second-ranked operator and continued to introduce new offers and services for its customers this quarter.

These strong results confirm our ambition to deliver “stable +” EBITDAaL in 2026.

Spain

In millions of euros		3Q 2026	change comparable basis	change historical basis		4M 2026	change comparable basis	change historical basis
Revenue		1,910	3.5 %	–		2,558	3.1 %	–
Retail services (B2C+B2B)		1,368	(1.3)%	–		1,830	(1.0)%	–
Convergence		749	(3.9)%	–		995	(4.4)%	–
Mobile-only		402	(4.1)%	–		498	(3.4)%	–
Fixed-only		161	0.6 %	–		256	0.9 %	–
IT & Integration services		56	104.2 %	–		81	115.1 %	–
Wholesale		179	3.6 %	–		231	3.7 %	–
Equipment sales		353	28.0 %	–		472	28.5 %	–
Other revenue		10	(14.4)%	–		26	(41.1)%	–

Note: Orange España (formerly MasOrange) was accounted for using the equity method for the first five months of 2026 and has been fully consolidated since June 2026.

Improving trend in service revenue

MasOrange became Orange España on 23 September. This marks a new chapter for Orange, strengthening the brand’s visibility and reaffirming its long-term commitment to the country.

In the third quarter of 2026, revenue in Spain reached €1,910 million, up +3.5%, driven by equipment sales (+28%) and wholesale services (+3.6%). The retail services revenue trend improved compared to the previous quarter.

Commercial momentum continued to improve, with positive net adds in fixed broadband (+7k), mobile (+12k) and new services (+169k). Convergent ARPO rose to €53.1 (+€0.2 yoy).

New B2B wins with major ports, large cities and players in the security sector further strengthen our position as a leading provider of trusted private networks in Spain.

The target of low-single-digit EBITDAaL growth in Spain in the second half of 2026 is confirmed.

Africa & Middle East

In millions of euros		3Q 2026	change comparable basis	change historical basis		9M 2026	change comparable basis	change historical basis
Revenue		2,401	14.2 %	14.0 %		6,976	14.0 %	11.7 %
Retail services (B2C+B2B)		2,206	15.2 %	15.0 %		6,388	14.5 %	12.3 %
Mobile-only		1,868	15.0 %	14.9 %		5,412	14.7 %	12.5 %
Fixed-only		301	12.3 %	11.9 %		864	10.9 %	8.8 %
IT & Integration services		38	53.8 %	54.0 %		111	38.4 %	34.6 %
Wholesale		148	(1.7)%	(2.6)%		464	5.3 %	2.5 %
Equipment sales		31	19.9 %	19.2 %		82	16.2 %	12.9 %
Other revenue		16	67.0 %	67.0 %		43	41.7 %	37.0 %

Record double-digit growth

Africa and Middle East confirmed their role as a growth driver for the Group, with third-quarter revenue of €2,401 million, a record increase of +14.2%.

All countries contributed to this outstanding performance driven by retail services (+15.2%) and supported by strong momentum across all key growth drivers: mobile data revenue (+20.2%), fixed broadband (+15.0%), Orange Money (+14.6%) and across B2B activities (+23.1%).

These results reflect an excellent commercial performance, with strong growth in our customer base as of 30 September 2026: 180 million mobile customers (+4.2% yoy), 98 million 4G customers (+11.0%), 54 million Orange Money customers (+21.8%) and nearly 5.4 million fixed broadband customers (+15.7%). Average mobile-only ARPO rose by +7.5% in the third quarter.

These achievements confirm the outlook for double-digit EBITDAaL growth in 2026.

Europe 6

In millions of euros		3Q 2026	change comparable basis	change historical basis		9M 2026	change comparable basis	change historical basis
Revenue		1,896	5.3 %	4.5 %		5,502	4.5 %	3.6 %
Retail services (B2C+B2B)		1,387	5.2 %	4.4 %		4,044	4.2 %	3.8 %
Convergence		406	6.7 %	6.0 %		1,199	6.7 %	6.3 %
Mobile-only		552	0.5 %	(0.1)%		1,631	(0.1)%	(0.5)%
Fixed-only		232	(4.4)%	(5.1)%		706	(3.5)%	(3.9)%
IT & Integration services		196	34.9 %	33.4 %		507	29.6 %	28.8 %
Wholesale		215	(2.0)%	(2.7)%		627	1.7 %	1.3 %
Equipment sales		276	10.4 %	9.6 %		771	7.1 %	6.7 %
Other revenue		18	42.1 %	41.2 %		60	22.9 %	(17.0)%

Strong revenue growth, with convergent offers gaining momentum

In the third quarter, Europe 6 generated revenue of €1,896 million, up a solid +5.3%. Retail services increased +5.2%, driven by strong commercial momentum in convergent offers (+6.7%) and exceptional IT & Integration services performance, mainly in Poland and Romania.

Europe 6 recorded strong net adds in the third quarter across mobile (+145k), convergence (+27k) and fiber (+71k).

The performance in Poland was particularly strong with convergent ARPO up +5.0% yoy, while quarterly revenue increased +7.9%. Moreover, the completion of the acquisition of Nexera acquisition by our FiberCo, co-controlled with APG, strengthens the joint venture’s growth prospects and expands Orange Poland’s fiber footprint.

Based on these very strong third-quarter results, the Europe 6 EBITDAaL growth outlook of mid-single-digit growth in 2026 is confirmed.

Orange Business

In millions of euros		3Q 2026	change comparable basis	change historical basis		9M 2026	change comparable basis	change historical basis
Revenue		1,717	(2.5)%	(1.7)%		5,219	(2.9)%	(4.0)%
Fixed-only		607	(10.0)%	(8.8)%		1,865	(9.2)%	(9.2)%
Voice		145	(12.5)%	(12.4)%		444	(12.5)%	(12.7)%
Data		462	(9.1)%	(7.6)%		1,421	(8.2)%	(8.0)%
IT & Integration services		904	4.0 %	4.6 %		2,707	2.2 %	(0.3)%
Mobile		206	(5.2)%	(5.2)%		647	(3.5)%	(3.5)%
Mobile-only		162	(4.5)%	(4.5)%		490	(5.3)%	(5.3)%
Wholesale		4	(17.6)%	(17.6)%		11	(17.6)%	(17.6)%
Equipment sales		40	(7.0)%	(7.0)%		147	4.3 %	4.3 %

Accelerating transformation in a complex environment

Orange Business generated revenue of €1,717 million in the third quarter of 2026, down -2.5%, as the macroeconomic environment weighed on activity.

Against this backdrop, Orange Business continues to execute its transformation plan, which aims to accelerate the go-to-market of its AI and trusted cloud solutions, particularly to the defense and security sectors, while accelerating efficiency notably through AI and its international partnership with Tech Mahindra.

In the third quarter, Orange Business obtained a new SecNumCloud qualification, strengthening its trusted cloud portfolio. Orange Business was also selected to provide the backbone of the European Union’s network for trusted data exchange.

Orange Cyberdefense accelerated its growth to +12.2% over the first nine months of the year, reaching €1 billion in revenue.

Orange Cyberdefense is commercializing its Dynamic SOC platform in nine European countries and has deployed Qevlar AI solution across 36 Security Operations Centers, reducing threat detection and analysis times.

However, the complex market environment is weighing on EBITDAaL improvement trend.

TOTEM

In millions of euros		3Q 2026	change comparable basis	change historical basis		9M 2026	change comparable basis	change historical basis
Revenue		173	(2.9)%	(2.9)%		532	(1.7)%	(1.7)%
Wholesale		173	(2.9)%	(2.9)%		532	(1.7)%	(1.7)%
Other revenue		–	–	–		–	–	–

TOTEM’s revenue was €173 million in the third quarter, down -2.9%. Growth in revenue from hosting third-party operators (+10.7%) only partly offset the decline in low-margin survey activities. The tenancy ratio has now reached 1.5x, which was the target set for 2026 when TOTEM was launched.

International Carriers & Shared Services

In millions of euros		3Q 2026	change comparable basis	change historical basis		9M 2026	change comparable basis	change historical basis
Revenue		321	5.2 %	5.2 %		910	1.2 %	1.0 %
Wholesale		196	(1.9)%	(1.9)%		569	(3.7)%	(3.9)%
Other revenue		125	18.9 %	18.5 %		341	10.7 %	10.3 %

Revenue from International Carriers & Shared Services increased +5.2% in the third quarter, mainly driven by Orange Marine’s activities.

Calendar of upcoming events

18 February 2027        – Publication of Full-Year 2026 financial results

Contacts

press: Eric Fohlen-Weill eric.fohlen-weill@orange.com Tom Wright tom.wright@orange.com Fatima Rahil fatima.rahil@orange.com

financial communication: (analysts and investors) Constance Gest constance.gest@orange.com Aurélia Roussel aurelia.roussel@orange.com Hong Hai Vuong honghai.vuong@orange.com Clarisse Quellec clarisse.quellec@orange.com Damien Levesque damien.levesque@orange.com

Disclaimer

This press release contains forward-looking statements about Orange’s financial situation, results of
operations and strategy. Forward-looking statements are statements that are not historical facts.
These statements include, without limitation, projections and estimates and their underlying
assumptions, statements regarding plans, objectives, intentions and expectations with respect to
future financial results and other events, prospects and statements regarding future performance.
Although we believe these statements are based on reasonable assumptions, they are subject to
numerous risks, uncertainties and assumptions, including matters not yet known to us or not currently
considered material by us, and which could cause actual results and developments to differ materially
from those expressed in, or implied or projected by, such forward-looking statements. There can be
no assurance that anticipated events will occur or that the objectives set out will actually be achieved.
More detailed information on the potential risks, uncertainties and assumptions that could affect our
financial results include those described or identified in any public documents filed with the French
Financial Markets Authority (AMF) by Orange, including the Universal Registration Document filed on
2 April 2026 with the AMF. In light of these risks, uncertainties and assumptions, you should not
place undue reliance on any forward looking statements contained herein. Forward-looking statements
speak only as of the date they are made. Other than as required by law, Orange does not undertake
any obligation to update them in light of new information, future developments or any other reason.

Appendix 1: financial key indicators

Quarterly data

In millions of euros		3Q 2026	3Q 2025 comparable basis	3Q 2025 historical basis	variation comparable basis	change historical basis
Revenues		12,191	11,771	9,993	3.6 %	22.0 %
France		4,363	4,341	4,341	0.5 %	0.5 %
Spain		1,910	1,846	–	3.5 %	–
Europe 6		1,896	1,801	1,813	5.3 %	4.5 %
Africa & Middle-East		2,401	2,101	2,106	14.2 %	14.0 %
Orange Business		1,717	1,760	1,747	(2.5)%	(1.7)%
Totem		173	179	179	(2.9)%	(2.9)%
International Carriers & Shared Services		321	305	305	5.2 %	5.2 %
Intra-Group eliminations		(590)	(562)	(498)
EBITDAaL (1)		4,140	3,958	3,437	4.6 %	20.4 %
As % of revenues		34.0 %	33.6 %	34.4 %	0.3 pt	(0.4 pt)
eCAPEX		1,712	1,756	1,466	(2.5)%	16.7 %
As % of revenues		14.0 %	14.9 %	14.7 %	(0.9 pt)	(0.6 pt)
EBITDAaL – eCAPEX		2,428	2,202	1,971	10.3 %	23.2 %
(1) EBITDAaL presentation adjustments are described in Appendix 2.

30 September data

In millions of euros		9M 2026	9M 2025 comparable basis	9M 2025 historical basis	variation comparable basis	change historical basis
Revenues		33,138	32,014	29,846	3.5 %	11.0 %
France		13,034	12,910	12,910	1.0 %	1.0 %
Spain		2,558	2,481	–	3.1 %	–
Europe 6		5,502	5,266	5,309	4.5 %	3.6 %
Africa & Middle-East		6,976	6,120	6,245	14.0 %	11.7 %
Orange Business		5,219	5,374	5,438	(2.9)%	(4.0)%
Totem		532	541	541	(1.7)%	(1.7)%
International Carriers & Shared Services		910	898	901	1.2 %	1.0 %
Intra-Group eliminations		(1,593)	(1,577)	(1,498)
EBITDAaL (1)		10,268	9,793	9,112	4.8 %	12.7 %
As % of revenues		31.0 %	30.6 %	30.5 %	0.4 pt	0.5 pt
eCAPEX		4,893	4,855	4,489	0.8 %	9.0 %
As % of revenues		14.8 %	15.2 %	15.0 %	(0.4 pt)	(0.3 pt)
EBITDAaL – eCAPEX		5,374	4,938	4,623	8.8 %	16.2 %
(1) EBITDAaL presentation adjustments are described in Appendix 2.

NB : Orange España (formerly MasOrange) is accounted for using the equity method during the first five months of 2026 and is fully consolidated from June 2026 onward.

Appendix 2: adjusted data to income statement items

Quarterly data

		3Q 2026				3Q 2025 historical basis
In millions of euros		Adjusted data	Presentation adjustments	Income statement		Adjusted data	Presentation adjustments	Income statement
Revenues		12,191	–	12,191		9,993	–	9,993
External purchases		(5,323)	(5)	(5,328)		(3,986)	(0)	(3,986)
Other operating income		227	–	227		223	–	223
Other operating expense		(129)	(36)	(166)		(73)	(7)	(80)
Labor expenses		(2,017)	(1)	(2,017)		(1,950)	14	(1,936)
Operating taxes and levies		(391)	(1)	(393)		(319)	1	(318)
Gains (losses) on disposal of fixed assets, investments and activities		na	39	39		na	22	22
Restructuring costs		na	(46)	(46)		na	(21)	(21)
Depreciation and amortization of financed assets		(9)	–	(9)		(29)	–	(29)
Depreciation and amortization of right-of-use assets		(341)	–	(341)		(359)	(0)	(359)
Impairment of right-of-use assets		1	2	4		–	–	–
Interest expenses on liabilities related to financed assets		(1)	1	na		(3)	3	na
Interest expenses on lease liabilities		(68)	68	na		(59)	59	na
EBITDAaL		4,140	20	na		3,437	72	na
Significant litigation		(6)	6	na		1	(1)	na
Specific labor expenses		(0)	0	na		14	(14)	na
Fixed assets, investments and business portfolio review		39	(39)	na		22	(22)	na
Restructuring program costs		(45)	45	na		(21)	21	na
Acquisition and integration costs		(36)	36	na		(7)	7	na
Interest expenses on liabilities related to financed assets		na	(1)	(1)		na	(3)	(3)
Interest expenses on lease liabilities		na	(68)	(68)		na	(59)	(59)

30 September data

		9M 2026				9M 2025 historical basis
In millions of euros		Adjusted data	Presentation adjustments	Income statement		Adjusted data	Presentation adjustments	Income statement
Revenues		33,138	–	33,138		29,846	–	29,846
External purchases		(13,813)	(5)	(13,819)		(11,965)	1	(11,964)
Other operating income		725	–	725		633	–	633
Other operating expense		(462)	(14)	(476)		(261)	(23)	(283)
Labor expenses		(6,338)	(43)	(6,381)		(6,264)	(1,598)	(7,862)
Operating taxes and levies		(1,672)	(14)	(1,685)		(1,525)	0	(1,524)
Gains (losses) on disposal of fixed assets, investments and activities		na	2,598	2,598		na	64	64
Restructuring costs		na	(118)	(118)		na	(184)	(184)
Depreciation and amortization of financed assets		(33)	–	(33)		(88)	–	(88)
Depreciation and amortization of right-of-use assets		(1,083)	–	(1,083)		(1,074)	2	(1,072)
Impairment of right-of-use assets		(1)	(36)	(37)		–	(37)	(37)
Interest expenses on liabilities related to financed assets		(3)	3	na		(9)	9	na
Interest expenses on lease liabilities		(190)	190	na		(182)	182	na
EBITDAaL		10,268	2,561	na		9,112	(1,584)	na
Significant litigation		36	(36)	na		(10)	10	na
Specific labor expenses		(39)	39	na		(1,606)	1,606	na
Fixed assets, investments and business portfolio review		2,598	(2,598)	na		64	(64)	na
Restructuring program costs		(155)	155	na		(208)	208	na
Acquisition and integration costs		(71)	71	na		(14)	14	na
Interest expenses on liabilities related to financed assets		na	(3)	(3)		na	(9)	(9)
Interest expenses on lease liabilities		na	(190)	(190)		na	(182)	(182)

Appendix 3: economic CAPEX to investments in property, plant and intangible investment

In millions of euros		3Q 2026	3Q 2025 historical basis		9M 2026	9M 2025 historical basis
Investments in property, plant and equipment and intangible assets		2,012	1,707		5,542	5,261
Financed assets		(0)	(2)		(1)	(18)
Proceeds from sales of property, plant and equipment and intangible assets (excluding telecommunication licenses)		(135)	(92)		(467)	(223)
Telecommunication licenses		(165)	(145)		(180)	(531)
eCAPEX		1,712	1,466		4,893	4,489

Appendix 4: key performance indicators

In thousand, at the end of the period					September 30 2026		September 30 2025 (historical basis)
Number of convergent customers					14,267		9,256
Number of mobile accesses (excluding MVNOs) (1)					322,310		269,736
o/w	Convergent customers mobile accesses				28,143		16,175
	Mobile only accesses				294,167		253,561
o/w	Contract customers mobile accesses				143,537		100,367
	Prepaid customers mobile accesses				178,773		169,369
Number of fixed accesses (2)					45,342		38,102
o/w	Fixed Retail accesses				34,249		26,815
	o/w	Fixed Broadband accesses			30,848		22,673
		o/w	Very high‑speed broadband fixed accesses		24,423		15,981
			Convergent customers fixed accesses		14,267		9,256
			Fixed accesses only		16,581		13,417
	o/w	Fixed Narrowband accesses			3,401		4,142
o/w	Fixed Wholesale accesses				11,093		11,288
Group total accesses (1+2)					367,652		307,838
2025 data is on a comparable basis and includes Orange España’s accesses (formerly MasOrange), fully consolidated in the Orange Group accounts since June 2026.

Key performance indicators (KPI) by country are presented in the “Orange investors data book Q3 2026” available on the Group’s website www.orange.com, under Finance/Results: https://www.orange.com/en/finance/information-financiere-et-extra-financiere

Appendix 5: glossary

Key figures

Data on a comparable basis: data based on comparable accounting principles, scope of consolidation and exchange rates are presented for previous periods. The transition from data on an historical basis to data on a comparable basis consists of keeping the results for the period ended and then restating the results for the corresponding period of the preceding year for the purpose of presenting, over comparable periods, financial data with comparable accounting principles, scope of consolidation and exchange rate. The method used is to apply to the data of the corresponding period of the preceding year, the accounting principles and scope of consolidation for the period just ended as well as the average exchange rate used for the income statement for the period ended. Changes in data on a comparable basis reflect organic business changes. Data on a comparable basis is not a financial aggregate as defined by IFRS and may not be comparable to similarly-named indicators used by other companies.

Retail services (B2C + B2B): aggregation of revenues from (i) Convergent services, (ii) Mobile-only services, (iii) Fixed-only services and (iv) IT & integration services (see definitions). Retail Services (B2C+B2B) revenues include all revenues of a given scope excluding revenues from wholesale services, equipment sales and other revenues (see definitions).

EBITDAaL or “EBITDA after Leases”: operating income (i) before depreciation and amortization of fixed assets, effects resulting from business combinations, impairment of goodwill and fixed assets, share of profits (losses) of associates and joint ventures, (ii) after interest on debts related to financed assets and on lease liabilities, and (iii) adjusted for significant litigation, specific labor expenses, fixed assets, investments and businesses portfolio review, restructuring programs costs, acquisition and integration costs and, where appropriate, other specific elements. EBITDAaL is not a financial aggregate as defined by IFRS standards and may not be directly comparable to similarly-named indicators in other companies.

eCAPEX or “economic CAPEX”: investments in property, plant and equipment and intangible assets excluding telecommunication licenses, excluding dismantling assets, excluding financed assets and excluding assets acquired through a business takeover, minus the price of disposal of fixed assets (excluding telecommunication licenses). eCAPEX is not a financial performance indicator as defined by IFRS standards and may not be directly comparable to indicators referenced by similarly-named indicators in other companies.

Organic Cash Flow (telecoms activities): organic cash flow all-in from telecom activities corresponds, for the perimeter of the telecoms activities, to net cash provided by operating activities, minus (i) lease liabilities repayments and debts related to financed assets repayments, and (ii) purchases and sales of property, plant and equipment and intangible assets, net of the change in the fixed assets payables, (iii) excluding net telecommunication licenses paid and significant litigations paid or received. Organic cash flow (telecoms activities) is not a financial aggregate defined by IFRS and may not be comparable to similarly-named indicators used by other companies.

Free cash flow all-in (telecoms activities): free cash flow all-in from telecom activities corresponds to net cash provided by operating activities, minus (i) purchases and sales of property, plant and equipment and intangible assets, net of the change in the fixed assets payables, (ii) repayments of lease liabilities and on debts related to financed assets, and (iii) payments of coupons on subordinated notes. Free cash flow all-in from telecom activities is not a financial aggregate defined by IFRS and may not be comparable to similarly-named indicators used by other companies.

Adjusted consolidated net income: adjusted consolidated net income corresponds to the consolidated net income (i) before the effects of significant litigation, specific labor expenses, review of fixed assets, investments and business portfolio, restructuring programs costs, acquisition and integration costs, (ii) before the effects resulting from business combinations, (iii) before impairment losses recognized as part of asset impairment tests, (iv) before amortization and impairment losses of other intangible and tangible assets related to business combinations, (v) before amortization and impairment losses of the copper network dismantling asset in France, (vi) before the net income from discontinued operations and, (vii) where appropriate, before other significant specific items, (viii) restated for the effects of these adjustments on financial result and income taxes. Adjusted consolidated net income is not a financial aggregate defined by IFRS and may not be comparable to similarly-named indicators used by other companies.

Adjusted earnings per share (EPS) – Group share Net income – Basic: adjusted earnings per share are calculated by dividing (i) adjusted net income for the year attributable to the shareholders of the Group, after deduction of the effect of coupons on subordinated notes, (ii) by the weighted average number of ordinary shares outstanding during the period. Adjusted earnings per share is not a financial aggregate defined by IFRS and may not be comparable to similarly-named indicators used by other companies.

Earnings per share (EPS) – Group share Net income – Basic: basic earnings per share are calculated by dividing (i) net income for the year attributable to the shareholders of the Group, after deduction of the effect of coupons on subordinated notes, by (ii) the weighted average number of ordinary shares outstanding during the period.

Return On Capital Employed (ROCE): ROCE (Return On Capital Employed) from telecoms activities corresponds to Net Operating Profit After Tax (NOPAT) for the year ended (N) divided by Net Operating Assets (NOA) for the previous year (N-1).

Net Operating Profit After Tax (NOPAT) for the year ended (N) corresponds to operating profit (i) after interest on lease liabilities and on debts related to financed assets, and (ii) after income tax adjusted for the tax impact of financial income excluding interest on lease liabilities and on debts related to financed assets (tax charge calculated on the basis of the statutory tax rate applicable in France, the tax jurisdiction of the parent company Orange SA).

Net Operating Assets (NOA) for the previous year (N-1) correspond to (i) equity and (ii) financial liabilities and derivative liabilities (non‑current and current), excluding debts on financed assets, (iii) less financial assets and derivative assets (non‑current and current), cash and cash equivalents, including investments in Mobile Financial Services.

ROCE from telecoms activities is not a financial aggregate defined by IFRS and may not be comparable to similarly-named indicators used by other companies.

Performance indicators

Fixed retail accesses: number of fixed broadband accesses (FTTx, cable, xDSL, Fixed-4G / Fixed-5G, satellite and others) and fixed narrowband accesses (mainly PSTN).

Fixed wholesale accesses: number of fixed broadband and narrowband wholesale accesses operated by Orange.

Convergence

Convergent services: customer base and revenues from B2C Convergent retail offers, excluding equipment sales (see definition) defined as an offer combining at least a broadband access (FTTx, cable, xDSL, Fixed-4G / Fixed-5G with cell-lock…) and a mobile voice contract.

Convergent ARPO: average quarterly revenues per convergent offer (ARPO) calculated by dividing revenues from retail Convergent services offers invoiced to B2C customers generated over the past three months (excluding IFRS 15 adjustments) by the weighted average number of retail Convergent offers over the same period. ARPO is expressed by monthly revenues per convergent offer.

Mobile-only services

Mobile-only services: revenues from mobile offers (mainly outgoing calls: voice, SMS and data) invoiced to retail customers, excluding convergent services and equipment sales (see definitions). The customer base includes customers with a contract excluding retail convergence, machine-to-machine contracts and prepaid cards.

Mobile-only ARPO: average quarterly revenues from Mobile-only (ARPO) calculated by dividing revenues from Mobile-only retail services (excluding machine-to-machine and IFRS 15 adjustments) generated over the past three months by the weighted average of Mobile-only customers (excluding machine-to-machine) over the same period. The ARPO is expressed as monthly revenues per Mobile-only customer.

Fixed-only services

Fixed-only services: revenues from fixed retail offers, excluding B2C convergent offers and equipment sales (see definitions). It includes (i) fixed narrowband services (conventional fixed telephony), (ii) fixed broadband services, and (iii) business solutions and networks (with the exception of France, for which essential business solutions and networks are supported by Orange Business segment). For the Orange Business segment, Fixed-only service revenues include sales of network equipment related to the operation of voice and data services. The customer base consists of fixed narrowband and fixed broadband customers, excluding retail convergence customers.

Fixed-only Broadband ARPO: average quarterly revenues from Fixed-only Broadband (ARPO) calculated by dividing the revenue from Fixed-only Broadband retail services (excluding IFRS 15 adjustments) generated over the past three months by the weighted average of Fixed-only Broadband customers over the same period. ARPO is expressed as monthly revenues per Fixed-only Broadband customer.

IT & integration services

IT & Integration services: revenues from unified communication and collaboration services (Local Area Network and telephony, advising, integration and project management), hosting and infrastructure services (including Cloud Computing), applications services (customer relations management and other applications services), security services, video conferencing offers, machine-to-machine services (excluded connectivity) as well as sales of equipment related to the above products and services.

Wholesale

Wholesale: revenues from other carriers consists of (i) mobile services to other carriers including incoming traffic, visitor roaming, network sharing, national roaming and Mobile Virtual Network Operators (MVNOs), (ii) fixed services to other carriers including national networking, services to international carriers, high-speed and very high-speed broadband access (fibre access, unbundling of telephone lines and xDSL access sales) and the sale of telephone lines on the wholesale market, and (iii) equipment sales to other carriers.

Equipment sales

Equipment sales: revenues from all mobile and fixed equipment sales, excluding (i) equipment sales associated with the supply of IT & Integration services, (ii) sales of network equipment related to the operation of voice and data services in the Orange Business operating segment, (iii) equipment sales to other carriers, and (iv) equipment sales to dealers and brokers.

Other revenues

Other revenues: revenues including (i) equipment sales to external dealers and brokers, (ii) revenues from portals, online advertising and transverse activities of the Group, (iii) revenues from the removal of copper cables, and (iv) other miscellaneous revenues.

---

1 Unless otherwise stated, percentage changes are year-on-year performance versus the third quarter of 2025 on a comparable basis.
2 Following the creation of the Spain segment, the former “Europe” segment has been renamed “Europe 6” and includes Poland, Belgium, Luxembourg, Slovakia, Romania and Moldova.
3 Public Switched Telephone Network (PSTN)
4 Excluding costs related to Orange Bank discontinuation.
5 Subject to approval by the shareholders’ meeting.

Attachment

• PR_ORANGE_Q3_2026_EN_271026

EXOSENS DELIVERS +23.5% REVENUE GROWTH IN Q3 2026, DRIVEN BY STRONGER DEMAND AND FASTER-THAN-EXPECTED CAPACITY RAMP-UP

FULLY ON TRACK TO MEET UPGRADED 2026 OUTLOOK

HIGHLIGHTS

• Group revenue up +18.0% to €386.9 million in 9M 2026, including +14.4% LFL¹; clear acceleration in Q3 to +23.5%, including +20.5% LFL (vs. +11.4% LFL in H1), driven by strong commercial momentum and faster-than-expected capacity ramp-up
  • Amplification revenue up +15.5% in 9M 2026, with growth accelerating to +23.9% in Q3, driven by increasing global demand for high-performance image intensifier tubes in mission-critical night vision applications and faster-than-expected ramp-up of additional European production capacity
  • D&I revenue up +23.7% in 9M 2026, including +14.1% LFL, reflecting the increasing adoption of Exosens’ advanced imaging solutions across defense and surveillance markets, particularly in drone and counter-drone applications, alongside strong momentum in nuclear instrumentation, notably for next-generation SMRs
• Adjusted gross margin up +16.1% to €194.9 million in 9M 2026 (margin of 50.4%), with double-digit growth across Amplification (+14.1%) and D&I (+21.1%) segments
• Key milestone in the U.S.: first delivery order for 1,600 BiNOD systems, establishing Exosens as a supplier of complete night vision systems to the U.S. Army
• Strong operational execution: image intensifier tube production capacity on track to increase by 40% across Europe and the U.S. by 2027, with the first phase in Europe implemented and production ramping up faster than expected
• Scaling production of advanced imaging solutions: capacity set to triple for thermal cameras and double for cooled infrared cameras in 2026, to meet growing demand across drone, counter-drone and long-range surveillance applications

OUTLOOK

• Upgraded 2026 outlook confirmed: c.20% revenue growth and c.25% adjusted EBITDA growth at midpoint vs. 2025, implying further profitability improvement
  • Revenue in the range of €558 million to €570 million
  • Adjusted EBITDA in the range of €186 million to €192 million
  • Capital expenditure at around 9% of revenue (excluding capitalized R&D), driven by production capacity expansion in Europe and the United States

Press release, Mérignac (France), 27 October 2026 – Exosens (EXENS; FR001400Q9V2), a high-tech company focused on providing mission- and performance-critical amplification, detection and imaging technologies, today publishes its revenue and adjusted gross margin for the nine-month period ended 30 September 2026.

“Our nine-month performance demonstrates both strong commercial momentum and disciplined execution, with revenue growth reaching +18.0% over the period and accelerating to +23.5% in the third quarter. In Amplification, our additional European capacity for image intensifier tubes is ramping up ahead of plan, enabling us to serve strong demand for night vision solutions sooner than anticipated, while our first BiNOD delivery order marks a key step in building our presence in the U.S. market. In D&I, our advanced imaging technologies continue to gain traction in drone, counter-drone and long-range surveillance applications, as we scale production capacity to meet growing demand. Further progress in next-generation nuclear projects, particularly in SMRs, also reinforces our long-term growth prospects. Building on this sustained momentum, we are fully on track to meet our upgraded 2026 guidance,” said Jérôme Cerisier, CEO of Exosens.

Revenue up +18.0% in 9M 2026, with growth accelerating to +23.5% in Q3 2026, driven by strong commercial momentum and faster-than-expected capacity ramp-up

In € millions	9M 2025	9M 2026	Change (€m)	Change (%)	LFL (%)
Amplification	231.8	267.8	+36.0	+15.5%	+14.5%
Detection & Imaging	97.0	120.0	+23.0	+23.7%	+14.1%
Eliminations & Other	(0.9)	(0.9)	0.0	nm	nm
Total revenue	327.8	386.9	+59.1	+18.0%	+14.4%

Consolidated revenue amounted to €386.9 million in 9M 2026, up +18.0% (+€59.1 million) compared with €327.8 million in 9M 2025. This performance reflects the contributions from 2025 and 2026 acquisitions and strong like-for-like growth of +14.4%, driven by growing demand for mission-critical night vision and imaging solutions in defense and surveillance applications, alongside strong momentum in nuclear instrumentation. Growth accelerated markedly in Q3 2026 to +23.5%, including +20.5% like-for-like.

AMPLIFICATION

Amplification revenue amounted to €267.8 million (c.69% of Group sales) in 9M 2026, up +15.5% (+€36.0 million) compared with 9M 2025, including strong like-for-like growth of +14.5%. This sustained performance reflects increased image intensifier tube sales volumes and improved yields, together with the expected increase in NVLS’ contribution as the year progressed. Revenue growth accelerated to +23.9% in Q3 2026, from +11.6% in H1 2026, as additional European production capacity ramped up faster than expected.

Growing global defense spending and multi-year programs to modernize armed forces are accelerating the procurement of advanced night vision systems. Against this backdrop, Exosens builds on its position as the world’s leading supplier of high-performance, ITAR-free image intensifier tubes. The Group’s technological leadership and scalable industrial capabilities enable it to meet growing demand from NATO and allied armed forces.

Demand continued to exceed available production capacity in 9M 2026. In this context, Exosens’ ability to deliver higher volumes drove revenue growth, notably under major night vision procurement programs such as the OCCAR framework for the German and Belgian armed forces. Demand also continued to grow in other markets, particularly in Northern and Eastern Europe, as well as across several international markets. Adoption of 5G image intensifier technology also continued to expand among special forces in NATO countries.

Against this backdrop of accelerating global demand, Exosens continues to implement its investment plan to expand production capacity across Europe and the United States by 40% by 2027. The first phase in Europe was successfully implemented, with an extended operating schedule enabling production to run throughout August for the first time, while newly installed production equipment was commissioned. As a result, additional European production capacity ramped up faster than expected, enabling the Group to meet growing demand sooner than anticipated.

In the U.S., the rollout of the new manufacturing facility is underway, establishing scalable in-country production capacity to support future growth in the world’s largest single night vision market. Underscoring the effectiveness of its industrial strategy, Exosens reached a key milestone in August 2026 when its U.S. subsidiary, Photonis Defense, was awarded a first delivery order for 1,600 complete systems under the U.S. Army’s Binocular Night Observation Device (BiNOD) program, as part of the broader US$352.6 million Indefinite-Delivery/Indefinite-Quantity (IDIQ) contract announced in March 2026.

The order marks the transition from key testing and qualification to the Low-Rate Initial Production (LRIP) phase, laying the foundation for regular production of BiNOD systems in the United States. First product deliveries are expected by the end of 2026, with the bulk of deliveries scheduled throughout 2027. Photonis Defense will manufacture and test the complete BiNOD systems in the U.S., integrating Exosens’ high-performance image intensifier tubes.

DETECTION & IMAGING

D&I revenue reached €120.0 million (c.31% of Group sales) in 9M 2026, up +23.7% (+€23.0 million) compared with 9M 2025. This performance reflects the contributions from 2025 and 2026 acquisitions (Noxant, Phasics, Emberion) and strong like-for-like growth of +14.1%, driven by accelerating demand for advanced imaging solutions in defense and surveillance markets, particularly in drone and counter-drone applications, alongside strong momentum in nuclear instrumentation, notably for next-generation Small Modular Reactors (SMRs).

Defense & Surveillance

Imaging technologies are becoming central to modern defense operations, driven by two structural trends: (i) the growing integration of advanced optronic technologies into defense platforms, and (ii) the proliferation of drones and counter-drone systems that are becoming a core pillar of modern warfare and reshaping conventional defense operations. Against this favorable backdrop, Exosens is well positioned to capitalize on accelerating demand for advanced imaging solutions through its comprehensive portfolio of technologies enabling situational awareness, threat detection, identification and tracking, targeting, and long-range observation across a wide range of defense and surveillance applications.

Commercial momentum continued to build in 9M 2026, particularly in the fast-growing drone and counter-drone space, with Exosens’ advanced imaging solutions gaining further adoption among leading OEMs and autonomous defense systems developers. The Group’s understanding of UxV technological requirements and its support throughout the design-in phase help customers bring new systems to market faster. In addition, its agile supply chain and scalable industrial capabilities allow it to respond swiftly to accelerating market demand.

Surveillance markets also gained further momentum, driven by increasing investment in homeland security and counter-drone capabilities amid growing concerns over ground and airborne incursions. Demand was particularly strong for advanced imaging solutions used in long-range observation and counter-drone systems, with Exosens’ technologies increasingly adopted by leading OEMs and system integrators.

To meet growing demand, Exosens is implementing plans to triple production capacity for thermal cameras and double capacity for cooled infrared cameras in 2026. Together, these increases highlight the Group’s ability to anticipate evolving market requirements and scale production accordingly.

Commercial Markets

In Nuclear, demand for advanced detectors and instrumentation remained strong in 9M 2026, driven by growing investment in next-generation nuclear technologies, particularly SMRs. The nuclear market continues to benefit from rising demand for reliable, carbon-free power, driven by the rapid expansion of AI data centers and their substantial energy needs, reinforcing the long-term prospects for SMRs.

In the U.S., progress under the Department of Energy’s (DOE) Reactor Pilot Program highlights the accelerating deployment of next-generation reactors. Exosens supplied advanced neutron flux monitoring detectors and related technical expertise to Antares Nuclear and Valar Atomics, the developers behind the first two reactor designs to reach criticality under the program. These milestones are expected to lead to pre-series production orders in the near term and support long-term demand for Exosens’ nuclear instrumentation solutions across the U.S. market.

In Industrial Control, market conditions continued to show signs of recovery in 9M 2026. The expansion of AI infrastructure is expected to drive investment in semiconductor manufacturing and industrial automation, supporting long-term structural demand for Exosens’ advanced imaging technologies in semiconductor inspection, machine vision and real-time process monitoring. The Group is well positioned to benefit from these trends through its cutting-edge portfolio of infrared, UV and wavefront sensing technologies.

In Life Sciences, market conditions were mixed in 9M 2026. Global uncertainty weighed on scientific research and demand for microscopy components, while inventory drawdowns in mass spectrometry, now complete, softened demand for advanced detectors. Despite these temporary headwinds, market fundamentals remain favorable, driven by the shift towards higher-performance mass spectrometry systems. Rising private-sector R&D, notably in low-carbon materials and semiconductor testing, also drives long-term demand for the Group’s electron microscopy detectors. In this context, Exosens has secured design-ins for its technologies in several major projects, supporting growth in the coming years.

M&A

On 24 April 2026, Exosens completed the acquisition of Emberion, a Finland- and UK-based company specializing in the design and manufacturing of innovative infrared sensors leveraging patented quantum dot imaging technology. This acquisition strengthens Exosens’ advanced imaging portfolio with emerging quantum dot-based short-wave infrared sensors, supporting new opportunities in surveillance imaging, notably for drone-based systems, and in industrial applications such as semiconductor inspection.

Adjusted gross margin up +16.1% in 9M 2026

	9M 2025		9M 2026		Change
	In €m	% of sales	In €m	% of sales	In €m	In %
Amplification	121.8	52.5%	138.9	51.9%	+17.1	+14.1%
Detection & Imaging	46.1	47.6%	55.9	46.6%	+9.7	+21.1%
Eliminations & Other	0.1	nm	0.2	nm	+0.1	nm
Adjusted gross margin	168.0	51.2%	194.9	50.4%	+27.0	+16.1%

The Group’s adjusted gross margin reached €194.9 million in 9M 2026, up +16.1% (+€27.0 million) compared with €168.0 million in 9M 2025. The margin rate decreased by (85) basis points to 50.4% in 9M 2026 (versus 51.2% in 9M 2025). This reflects product mix effects in both segments, driven by the ramp-up of NVLS’ deliveries of complete night vision systems and strong revenue growth in defense imaging. Staffing costs at the U.S. facility also weighed on the margin rate. These effects were partly offset by higher image intensifier tube sales volumes and improved yields. In addition, the comparison base was particularly high in Q3 2025. The Group’s upgraded full-year guidance already factors in these operating effects.

The Amplification segment’s adjusted gross margin totaled €138.9 million in 9M 2026, up +14.1% (+€17.1 million) compared with 9M 2025. The margin rate decreased by (68) basis points to 51.9% in 9M 2026 (versus 52.5% in 9M 2025). As expected, the ramp-up of NVLS’ deliveries of complete night vision systems in Q3 2026, following a limited contribution in H1 2026, resulted in a less favorable product mix year on year, as NVLS, acquired in July 2025, contributed negligible revenue in 9M 2025. Staffing costs at the U.S. facility also weighed on the segment’s margin rate. These effects were partly offset by higher image intensifier tube sales volumes and improved yields. In addition, the comparison base was particularly high in Q3 2025, when the segment’s margin rate reached 54.9%, versus 50.5% for full-year 2025.

The Detection & Imaging segment’s adjusted gross margin amounted to €55.9 million in 9M 2026, up +21.1% (+€9.7 million) compared with 9M 2025. The margin rate declined by (103) basis points to 46.6% in 9M 2026 (versus 47.6% in 9M 2025). This margin contraction reflects a less favorable product mix, driven by the increased weight of fast-growing defense imaging products relative to higher-margin detectors, particularly those used in life sciences.

Upgraded 2026 outlook confirmed: c.20% revenue growth and c.25% adjusted EBITDA growth at midpoint vs. 2025, implying further profitability improvement

Building on sustained commercial momentum, reflected in the clear acceleration in like-for-like revenue growth in the third quarter, as well as continued disciplined execution, Exosens confirms its upgraded full-year 2026 guidance announced on 17 September 2026.

The Group expects:

• Revenue in the range of €558 million to €570 million;
• Adjusted EBITDA in the range of €186 million to €192 million;
• Capital expenditure at around 9% of revenue (excluding capitalized R&D expenses of around 3% of revenue), driven by production capacity expansion in Europe and the U.S.

Exosens will communicate its full-year 2027 guidance upon publication of the Group’s full-year 2026 results on 22 February 2027.

Financial Calendar

• 22/02/2027: Full-year 2026 results (before market opening).

About Exosens

Exosens is a high-tech company with more than 85 years of experience in the innovation, development, manufacturing and sale of high-end electro-optical technologies in the fields of amplification, detection and imaging. Today, it offers its customers detectors and imaging solutions such as digital cameras, ion, electron, neutron and gamma-ray detectors as well as image intensifier tubes. This enables Exosens to address complex challenges in extremely demanding environments by providing its customers with tailor-made solutions. Thanks to its sustained investment, Exosens is internationally recognized as a major innovator in optoelectronics, with production and R&D activities carried out at 13 sites across Europe and North America and more than 2,000 employees. Exosens is listed on compartment A of the regulated market of Euronext Paris (Ticker: EXENS – ISIN: FR001400Q9V2). Exosens is a member of the Euronext Tech Leaders segment and is also included in several indices, including SBF 120, CAC All-Tradable, CAC Mid 60, FTSE Total Cap and MSCI France Small Cap. For more information: www.exosens.com.

Investor Relations

Laurent Sfaxi, l.sfaxi@exosens.com

Media Relations

Brunswick Group, exosens@brunswickgroup.com

APPENDICES

Quarterly figures for 9M 2026

In € millions	Q1 2026	Q2 2026	H1 2026	Q3 2026	9M 2026
Amplification	88.1	88.2	176.3	91.5	267.8
Detection & Imaging	34.6	42.8	77.4	42.5	120.0
Eliminations & Other	(0.2)	(0.5)	(0.6)	(0.3)	(0.9)
Total revenue	122.6	130.5	253.1	133.8	386.9
Growth (%)	19.7%	11.4%	15.3%	23.5%	18.0%
Like-for-like (%)	12.5%	10.3%	11.4%	20.5%	14.4%

In € millions	Q1 2026	Q2 2026	H1 2026	Q3 2026	9M 2026
Amplification	47.2	45.4	92.6	46.3	138.9
Detection & Imaging	16.2	21.1	37.2	18.6	55.9
Eliminations & Other	0.1	0.0	0.1	0.1	0.2
Adjusted gross margin	63.5	66.4	129.9	65.0	194.9
As a % of total revenue	51.8%	50.9%	51.3%	48.6%	50.4%

Quarterly figures for 9M 2025

In € millions	Q1 2025	Q2 2025	H1 2025	Q3 2025	9M 2025
Amplification	79.1	78.8	157.9	73.9	231.8
Detection & Imaging	24.0	38.3	62.3	34.7	97.0
Eliminations & Other	(0.7)	0.0	(0.7)	(0.2)	(0.9)
Total revenue	102.4	117.1	219.5	108.3	327.8

In € millions	Q1 2025	Q2 2025	H1 2025	Q3 2025	9M 2025
Amplification	41.1	40.2	81.2	40.5	121.8
Detection & Imaging	11.8	18.5	30.3	15.8	46.1
Eliminations & Other	0.0	0.0	(0.1)	0.1	0.1
Adjusted gross margin	52.9	58.6	111.5	56.5	168.0
As a % of total revenue	51.6%	50.1%	50.8%	52.1%	51.2%

Definitions

Like-for-like growth is defined as the revenue growth achieved by the Group, excluding currency effects and changes in the scope of consolidation. It corresponds to the revenue generated in period “n” by all companies included in the Group’s scope of consolidation at the end of period “n-1” (excluding any contribution from companies acquired since the end of period “n-1”), compared with the revenue generated in period “n-1” by the same companies. Accordingly, like-for-like growth for the nine-month period ended 30 September 2026 excludes the contributions of Noxant, NVLS, Phasics and Emberion, which were acquired by the Group in March 2025, July 2025, October 2025 and April 2026, respectively.

Adjusted gross margin is defined as the difference between the selling price and the cost of products and services (including employee benefits expense).

Adjusted EBITDA is defined as operating profit, excluding (i) depreciation, amortization and impairment losses on non-current assets, net of reversals; (ii) non-recurring income and expenses, as presented in the Group’s consolidated income statement under “Other income” and “Other expenses”; and (iii) items that do not reflect the Group’s ordinary operating performance (in particular, business reorganization and adaptation costs, costs relating to acquisitions and external growth transactions, as well as IFRS 2 share-based payment expense).

Forward-looking statements

Certain information included in this press release does not relate to historical facts but constitutes forward-looking statements. These forward-looking statements are based on current beliefs, expectations and assumptions, including, without limitation, assumptions regarding present and future business strategies and the environment in which Exosens operates, and involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those expressed in or implied by the forward-looking statements included in this press release. These risks and uncertainties include those set out and detailed in Chapter 4 “Risk factors and risk management system” of the Universal Registration Document filed on 9 March 2026 with the French financial markets authority (Autorité des marchés financiers – AMF) under number D.26-0072. Forward-looking statements speak only as of the date of this press release, and the Group expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements included in this press release to reflect any change in expectations or any change in events, conditions or circumstances on which these forward-looking statements are based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Group. Actual results could differ materially from those expressed in, or implied or projected by, forward-looking information and statements. This press release is provided for information purposes only. It does not constitute, and should not be deemed to constitute, an offer of securities to the public.

---

1 Like-for-like.

Attachment

• Exosens_Press Release_9M 2026_VA_FINAL

• The cobas smart e immunoanalyser – the newest addition to Roche’s industry-leading cobas immunoassay systems portfolio – is engineered to deliver central-lab performance in a footprint under one square metre. 
• With a planned menu of over 100 high-medical-value assays, and reaction times of 18 minutes or less for more than 90% of tests, the platform allows smaller laboratories to bring testing in-house, reducing turnaround times for patients.^1,2,3
• The cobas smart e uses the same reagents and Elecsys®  technology as Roche’s high-throughput platforms, optimising patient management with consistent test results over time and across different locations.

Basel, 27 October 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has received the CE Mark for its cobas smart e immunoanalyser, a compact, standalone platform engineered to deliver reliable testing with a planned menu of over 100 high-medical-value assays.^1,2 As the latest offering in Roche’s industry-leading cobas immunoassay systems portfolio, the platform bridges critical operational gaps across health systems by fitting central-laboratory precision into a footprint under one square meter. This enables decentralised sites to manage diverse testing demands directly in-house. With reaction times of 18 minutes or less across more than 90% of Roche immunoassays, local facilities can help reduce diagnostic turnaround times.^1,2

“For smaller hospitals and laboratories, maintaining central-lab quality has traditionally meant outsourcing tests,” said Matt Sause, CEO of Roche Diagnostics. “The cobas smart e immunoanalyser fits on a benchtop, bringing Roche’s immunoassay standards directly into these care settings. This means our cobas®  immunoassay solutions now span the full range of healthcare settings while delivering consistent high-quality results,  ensuring patients get timely, accurate answers, no matter where they live.”

The cobas smart e immunoanalyser joins the cobas®  e 402 and cobas®  e 801 analytical units, which run up to 60, 120 and 300 tests an hour respectively. Together, they scale from small local clinics to the highest-volume hospital laboratories, using the same universal reagents and Elecsys® technology, which helps ensure comparability of clinical results.

Across global healthcare systems, acute workforce shortages continue to strain diagnostic delivery, as health systems confront a projected global shortfall of 11 million health workers by 2030.⁴ The cobas smart e immunoanalyser combines minimal maintenance with guided, step-by-step tasks to simplify workflows and improve the productivity of lab personnel while also supporting the delivery of better patient care. Requiring just one single minute of daily operator intervention, the system reduces hands-on maintenance efforts by up to two-thirds compared to previous-generation platforms.^1,2

In addition to easing staffing pressures, the platform is engineered to withstand challenging physical and environmental conditions that often limit testing in decentralised settings. Equipped with an integrated water tank, standard power compatibility and a dust-protection design, the utility-independent engineering of the cobas smart e immunoanalyser bypasses traditional infrastructural barriers, enabling uninterrupted service across rural and resource-constrained clinics.^1,2

Featuring an expansive planned menu of over 100 high-medical-value assays across critical disease areas — including cardiometabolic, oncology and infectious diseases — the cobas smart e immunoanalyser enables low-volume labs to bring essential testing in-house, reducing the delay and cost of sending samples out.^1,2,3 Furthermore, because it utilises the same universal reagent carriers and Elecsys® technology as Roche’s high-throughput central laboratory platforms, it ensures comparability of clinical results across an entire hub-and-spoke network.^1,2

For more information, visit the Roche booth at the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Conference in New Delhi, India from 25 – 29 October 2026.

About the cobas smart e immunoanalyser
The cobas smart e immunoanalyser is the newest member of the cobas immunoassay testing family. It holds 36 reagent positions on a compact benchtop footprint of ~0.9 m² with a planned menu of over 100 assays, across a wide range of disease areas which will be launched in sequential waves.^1,2,3 Designed to support customers focused on maximising efficiency for their time, space and their teams, the cobas smart e immunoanalyser has a high uptime while requiring less hands-on time, with up to 2 hours of walk-away time on a load of 36 samples.^1,2 The possible immunoassay reaction time for routine and emergency samples are the lowest available on the central laboratory market, with a reaction time of 18 minutes or less for routine testing.^1,2 This new immunoanalyser complements cobas e 801 and cobas e 402 analytical units for immunoassay testing as it uses the same reagent packs, system reagents and well-established Elecsys technology. For more information, visit cobas.com.

To find out more about Roche’s cobas® smart e immunoanalyser, click here

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] cobas® smart e analyzer user guide – pre-launch version 0.1 – data on file
[2] Ref-13688 cobas e 411 Operator Manual V 3.3.1
[3} Ref: SWA assay menu and reagent specifications analysis | Data on file | Source: Reagent method sheets.
[4] World Health Organization. Health workforce. https://www.who.int/health-topics/health-workforce#tab=tab_1  (Accessed August 2026).

Roche Global Media Relations
Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com

Tristan Schmitz Phone: +41 79 529 70 35	Nathalie Altermatt Phone: +41 79 771 05 25
Lorena Corfas Phone: +41 79 568 24 95	Simon Goldsborough Phone: +44 797 32 72 915
Karsten Kleine Phone: +41 79 461 86 83	Kirti Pandey Phone: +41 79 398 38 53
Yvette Petillon Phone: +41 79 961 92 50	Irène Stephan Phone:  +41 79 377 83 75
Albert Thottiyil Phone: +41 79 775 66 12

Roche Investor Relations

Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com

Investor Relations North America

Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

Attachment

• Media&Investor Release CE Mark for cobas smart e English

Building on established clinical evidence, Dari-Dream is designed to further characterize the impact of QUVIVIQ on daytime functioning and support its inclusion in the US prescribing information.

Allschwil, Switzerland – October 27, 2026
Idorsia Ltd (SIX: IDIA) announced that the first patients are enrolled in Dari-Dream, a US label-enabling study evaluating QUVIVIQ^® (daridorexant) 50 mg in adults and elderly people with insomnia disorder.

Insomnia disorder is a chronic, 24-hour condition that impacts not only sleep at night but also how people feel and function during the day. Beyond difficulties falling or staying asleep, people with insomnia experience symptoms that affect alertness, cognition, mood, energy, and daily functioning.

QUVIVIQ is supported by an extensive body of clinical evidence demonstrating not only benefits across nighttime symptoms of insomnia, but also daytime functioning. In the Phase 3 program, meaningful improvement with the 50 mg dose was observed across all three IDSIQ domains of alert/cognition, mood, and sleepiness as well as the overall IDSIQ score. These findings are reflected in prescribing information in multiple countries worldwide, including across Europe.

Following discussions with the US Food and Drug Administration, Dari-Dream has been specifically designed to further characterize these outcomes and support their inclusion in US prescribing information. Inclusion of daytime functioning information in the US label would support broader physician and patient education on an aspect of insomnia treatment that is highly relevant to people living with the disorder.

Amer Joseph, MD, Chief Medical Officer and Head of Global Clinical Development at Idorsia commented:
“Insomnia is a 24-hour condition that affects patients both during the night and throughout the following day. Daridorexant was specifically designed to provide efficacy across the night while minimizing next-morning residual sleepiness. Importantly, its differentiated profile as an equipotent dual orexin receptor antagonist may also contribute directly to improvements in daytime functioning. Building on the extensive evidence generated during the clinical development program, Dari-Dream is designed to further characterize these outcomes and support their inclusion in US prescribing information.”

Roland Wandeler, Chief Executive Officer of Idorsia, commented:
“For people living with insomnia, the burden of the condition extends well beyond the night. Difficulties with alertness, mood, energy, and daily functioning can affect many aspects of everyday life. We have already generated compelling evidence demonstrating the benefits of daridorexant not only on sleep, but also daytime functioning. Dari-Dream is an important next step in our efforts to make this information available to healthcare professionals and patients in the US. Together with other initiatives aimed at enhancing the patient and physician experience, Dari-Dream forms part of our broader strategy to maximize the potential of QUVIVIQ for patients.”

About Dari-Dream (NCT07843329)
Dari-Dream is a Phase 3, randomized, double-blind, placebo-controlled study evaluating QUVIVIQ (daridorexant) 50 mg in adults and elderly people with insomnia disorder. Approximately 344 participants will be randomized to receive daridorexant 50 mg or placebo once nightly for three months. The study will evaluate changes in subjective total sleep time as its primary endpoint. Key secondary endpoints include the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) sleepiness domain and total score, assessing the physical, emotional, and cognitive consequences of insomnia during the day. Results are expected during 2028.

Notes to the editor

QUVIVIQ – a different kind of insomnia treatment
Insomnia affects millions worldwide, yet commonly used treatments can lead to next-day drowsiness, dependence, and withdrawal symptoms – leaving a clear unmet need for safer, effective alternatives.

Discovered by Idorsia, QUVIVIQ works differently from traditional hypnotics. As a dual orexin receptor antagonist, it selectively targets the orexin system, helping to regulate overactive wake signaling without broadly suppressing brain activity. Its optimized pharmacokinetics promote restorative sleep throughout the entire night, reducing morning sleepiness, and improving daytime functioning.

Clinical trials published in The Lancet Neurology demonstrated that daridorexant significantly improved sleep onset, sleep maintenance, and self-reported total sleep time at 25mg and 50mg doses compared to placebo. Daridorexant 50 mg also demonstrated a highly significant improvement in daytime functioning compared to placebo, findings that are reflected in prescribing information in multiple countries worldwide.

Idorsia is building QUVIVIQ into a global brand
QUVIVIQ is marketed by Idorsia in North America and Europe, and is available in key international markets in Asia-Pacific and the Middle East through commercial partnerships. Idorsia also has a license and supply agreement for Latin America.

IDSIQ^© 2020, University of Pittsburg. All rights reserved. IDSIQ-14 derivative created 2020 by Idorsia Pharmaceuticals Ltd under license and distributed by Idorsia Pharmaceuticals Ltd under license. IDSIQ is further a registered trademark of Idorsia Pharmaceuticals Ltd.

About Idorsia
The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients. To achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA).

For further information, please contact:
Investor & Media Relations
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com

The above information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “intend”, “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”, “pending” or “anticipates” or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company’s investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company’s existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Idorsia has transferred its rights for aprocitentan, cenerimod and selatogrel to Idorsia Investments SARL to allow the repayment of notes issued in connection with the repurchase offer completed in August 2025. More details on the transfer can be found in the current Financial Report.

Attachment

• Press Release PDF

AS LHV Group has decided the company’s financial calendar for the 2027 financial year.

In 2027 LHV Group plans to disclose information and organise the Annual General Meeting of shareholders according to the following schedule:

09.02.2027	Q4 2026 and unaudited full year results
16.02.2027	Disclosure of Financial Plan
16.02.2027	January results
09.03.2027	Audited results for 2026
16.03.2027	February results
31.03.2027	Annual General Meeting
20.04.2027	Q1 interim results
11.05.2027	April results
15.06.2027	May results
20.07.2027	Q2 interim results
10.08.2027	July results
14.09.2027	August results
19.10.2027	Q3 interim results
16.11.2027	October results
14.12.2027	November results

 
LHV Group is the largest domestic financial group and capital provider in Estonia. LHV Group’s key subsidiaries are LHV Pank, LHV Varahaldus, LHV Kindlustus and LHV Bank Limited. The Group employs approximately 1,200 people. The services of LHV Pank are used by over 517,000 customers, the II pillar pension funds managed by LHV have 104,000 active customers and LHV Kindlustus protects a total of 246,000 customers. LHV Bank Limited, a subsidiary of the Group, holds a banking licence in the United Kingdom and provides banking services to international financial technology companies, as well as loans to small and medium-sized enterprises. 

Investor Relations 
Sten Hans Jakobsoo 
Head of Investor Relations and Corporate Development 
Email: stenhans.jakobsoo@lhv.ee 

Communications 
Paul Pihlak 
Head of Communications 
Email: paul.pihlak@lhv.ee  

• 2026 operating profit expected to reach CHF 115 million (previously CHF 70 million) driven by higher than expected Cresemba and Zevtera-related revenue of CHF 250 million (previously CHF 210 million)
• Cumulative cash flow target for “Agenda 2030” raised to CHF 650 million (previously CHF 600 million)
• Updates on design of late-stage clinical program for ceftibuten-ledaborbactam and progress of fosmanogepix phase 3 studies
• Capital Markets Day on October 28, 2026

Ad hoc announcement pursuant to Art. 53 LR

Allschwil, Switzerland, October 27, 2026

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it is raising its financial guidance for the full year 2026 and the cumulative cash flow target for 2026-2030 from its commercialized products within the strategic initiative, “Agenda 2030”. The company also provided updates on the progress of its late-stage clinical programs for ceftibuten-ledaborbactam and fosmanogepix, ahead of its Capital Markets Day taking place tomorrow in Zurich.

David Veitch, Chief Executive Officer, said: “The sustained momentum of our commercial business reinforces the financial foundations of our “Agenda 2030” and enhances our capacity to continue to invest in future growth. By 2030, we aim to establish a diversified business with four commercialized products and an industry-leading anti-infectives R&D pipeline. We look forward to engaging with investors, analysts and media at tomorrow`s Capital Markets Day in Zurich as we outline the next phase of Basilea’s growth.”

Adesh Kaul, Chief Financial Officer, added: “Cresemba’s continued strong growth underscores the quality and durability of our commercial franchise. The significant increase in expected milestone income allows us to raise our full-year 2026 guidance for Cresemba and Zevtera-related income to CHF 250 million, 19% above our previous guidance. Given Cresemba’s sustained momentum, we are also increasing our “Agenda 2030” target for cumulative cash flow from Cresemba and Zevtera from CHF 600 million to CHF 650 million. This enhanced outlook strengthens our ability to fund future growth initiatives.”

Regarding the update of the late-stage clinical program for ceftibuten-ledaborbactam, Dr. Marc Engelhardt, Chief Medical Officer, stated: “Our recent consultations with the FDA and EMA have provided greater clarity on a streamlined clinical development pathway for ceftibuten-ledaborbactam and the data package required to support our targeted positioning: aiming for a broad, unrestricted use for patients with complicated urinary tract infections. As a result, we are now planning a phase 2/3 study under one study umbrella, without a separate confirmatory phase 3 study, and remain on track to initiate this study mid-2027. This approach will require fewer patients than running a program with two separate phase 3 studies and offers the opportunity for a data readout from the phase 2 part as early as end-2028. We are currently focused on completing the remaining preparatory work, including; finalizing the phase 2/3 study protocol, completing the ongoing phase 1 study providing further tolerability and safety data¹, complementary PK/PD analysis and securing clinical trial material.”

On the progress of its late-stage clinical program for fosmanogepix^{2, 3}, he added: “Our global phase 3 program for fosmanogepix progresses toward data readouts in mid-2028. We have successfully completed recruitment into the salvage therapy cohort of the invasive mold infection study, marking another important program milestone, while recruitment continues in the mold study’s other cohorts and in the invasive candidiasis study. Our goal is to maximize the potential of fosmanogepix by pursuing the broadest possible label at launch. We therefore plan to include results from both phase 3 studies in our initial regulatory filings.”

Increased full-year 2026 revenue guidance and raised cumulative cash flow target for “Agenda 2030”

Basilea provides the following updated guidance for the full year (FY) 2026 versus FY 2025:

(in CHF million / percent)	FY 2026 updated guidance	FY 2026 previous guidance	FY 2025 Actuals
Cresemba and Zevtera-related revenue	~250	~210	194.4
Total revenue	~310 (~33% increase)	~15% increase	232.4
Research & development expenses	~125 (~18% increase)	~20% increase	105.9
Operating profit	~115 (~123% increase)	~40% increase	51.5

• Cresemba and Zevtera-related revenue is now expected to increase to CHF ~250 million (versus CHF ~210 million previous guidance) with a cash contribution of CHF ~215 million (versus CHF ~180 million previous guidance). Milestone payments are now expected to reach CHF ~65 million (versus CHF ~35 million previous guidance).
• Within “Agenda 2030”, this results in an expected increase of cumulative cash flow from Cresemba and Zevtera from 2026 to 2030 to CHF 650 million (previously: CHF 600 million).

Basilea conducts Capital Markets Day tomorrow in Zurich, October 28, 2026

The event will provide the audience with a comprehensive update on the company’s strategic direction and value drivers and will include presentations from senior management and external experts. For further details on the agenda and registration, please visit https://basilea-cmd.com/#E4A948

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Fosmanogepix and ceftibuten-ledaborbactam

These projects have been funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA). Fosmanogepix is funded under OT number: 75A50124C00033 and ceftibuten-ledaborbactam under contract 75A50123C00050. The contracts and federal funding are not an endorsement of the study results, product, or company.

For further information, please contact:

Peer Nils Schröder, PhD Head of Corporate Communications & Investor Relations Basilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b 4123 Allschwil Switzerland
Phone	+41 61 606 1102
E-mail	media_relations@basilea.com investor_relations@basilea.com

This ad hoc announcement can be downloaded from www.basilea.com.

References

1. ClinicalTrials.gov identifier: NCT06733675
2. FAST-IC (Fosmanogepix Against Standard-of-care Treatment in Invasive Candidiasis: ClinicalTrials.gov identifier: NCT05421858
3. FORWARD-IM (FOsmanogepix study Run Worldwide as Antifungal treatment in Resistant Disease caused by Invasive Molds): ClinicalTrials.gov identifier: NCT06925321

Attachment

• Press release (PDF)

Ad hoc announcement pursuant to Art. 53 LR

Third quarter

• Q3 net sales grew +4% (cc^¹, +4% USD), with core operating income^¹ +10% (cc, +11% USD)
  • Sales growth driven by priority brands including Kisqali (+37% cc), Kesimpta (+22% cc), Scemblix (+67% cc), Leqvio (+63% cc) and Cosentyx (+9% cc)
  • Core operating income margin^¹ was 41.6%, +2 percentage points (cc)
• Q3 operating income declined -61% (cc, -59% USD) mainly due to a partial impairment of the del-desiran asset; net income down -71% (cc, -70% USD)
• Q3 core EPS^¹ grew +8% (cc, +9% USD) to USD 2.46
• Q3 free cash flow^¹ was USD 5.1 billion (-18% USD)
• 9 months net sales (0% cc, +2% USD) and core operating income (-2% cc, -1% USD) broadly in line with PY
• Q3 selected innovation milestones:
  • Remibrutinib positive PhIII REMODEL-1 and -2 results in RMS
  • Rhapsido FDA approval in most prevalent form of CIndU
  • Pluvicto FDA and CN approvals in mAPMN/S prostate cancer
  • Pelabresib EU submission completed in MF
  • Del-zota FDA priority review granted for DMD44
• Full-year 2026 guidance²  raised for core operating income
  • Net sales expected to grow low single-digit (unchanged)
  • Core operating income expected to be in line to grow low single-digit (from decline low single-digit)

Basel, October 27, 2026 – Commenting on Q3 2026 results, Vas Narasimhan, CEO of Novartis, said:
“Novartis delivered solid sales growth in Q3, as priority brands and launches more than offset generic erosion, demonstrating the replacement power of the business. Combined with productivity efforts, this drove strong bottom-line performance and allowed us to upgrade our full-year guidance. At the same time, we continued to advance our pipeline, with positive Phase III results for remibrutinib in RMS, label expansions for Rhapsido and Pluvicto in the US, and the first submission for pelabresib in the EU. While the del-desiran readout in DM1 was not what we had hoped, we saw evidence of clinical activity in the data and are working through the development path for this medicine. Importantly, our programs in FSHD and DMD continue to progress well. With continued momentum across the business and pipeline, we remain well on track to deliver our mid- and long-term outlook.”

Key figures
	Q3 2026	Q3 2025	% change			9M 2026	9M 2025	% change
	USD m3	USD m3	USD	cc		USD m3	USD m3	USD	cc
Net sales	14 522	13 909	4	4		42 043	41 196	2	0
Operating income	1 843	4 501	-59	-61		10 828	14 028	-23	-24
Net income	1 196	3 930	-70	-71		7 609	11 563	-34	-35
EPS (USD)	0.63	2.04	-69	-70		4.01	5.94	-32	-33
Free cash flow	5 111	6 217	-18			14 002	15 941	-12
Core operating income	6 036	5 460	11	10		16 873	16 960	-1	-2
Core net income	4 655	4 330	8	6		13 027	13 522	-4	-5
Core EPS (USD)	2.46	2.25	9	8		6.85	6.94	-1	-3

1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 45 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.    2. Please see detailed guidance assumptions on page 7.    3. USD millions unless indicated otherwise.

Strategy

Our focus

Novartis is a “pure-play” innovative medicines company. We have a clear focus on four core therapeutic areas (cardiovascular-renal-metabolic, immunology, neuroscience and oncology), with multiple significant in-market and pipeline assets in each of these areas, that address high disease burden and have substantial growth potential. In addition to two established technology platforms (chemistry and biotherapeutics), three emerging platforms (gene & cell therapy, radioligand therapy and xRNA) are being prioritized for continued investment into new R&D capabilities and manufacturing scale. Geographically, we are focused on growing in our priority geographies – the US, China, Germany and Japan.

Our priorities

1. Accelerate growth: Renewed attention to deliver high-value medicines (NMEs) and focus on launch excellence, with a rich pipeline across our core therapeutic areas.
2. Deliver returns: Continuing to embed operational excellence and deliver improved financials. Novartis remains disciplined and shareholder-focused in our approach to capital allocation, with substantial cash generation and a strong capital structure supporting continued flexibility.
3. Strengthen foundations: Unleashing the power of our people, scaling data science and technology, and continuing to build trust with society.

Financials

Third quarter

Net sales were USD 14.5 billion (+4%, +4% cc), with volume growth contributing 14 percentage points, partly offset by 9 percentage points from generic competition. Pricing had a negative impact of 1 percentage point, and currency had no impact.

Operating income was USD 1.8 billion (-59%, -61% cc), declining mainly due to higher R&D expenses, including a USD 1.9 billion partial impairment charge of the del-desiran IPR&D asset, and higher other expense, partly offset by higher net sales.

Net income was USD 1.2 billion (-70%, -71% cc), declining mainly due to lower operating income and higher interest expense. EPS was USD 0.63 (-69%, -70% cc).

Core operating income was USD 6.0 billion (+11%, +10% cc), mainly driven by higher net sales. Core operating income margin was 41.6% of net sales, increasing 2.3 percentage points (2.0 percentage points in cc).

Core net income was USD 4.7 billion (+8%, +6% cc), driven by higher core operating income, partly offset by higher interest expense. Core EPS was USD 2.46 (+9%, +8% cc), benefiting from the lower weighted average number of shares outstanding.

Free cash flow amounted to USD 5.1 billion (-18%), declining due to lower net cash flows from operating activities.

Nine months

Net sales were USD 42.0 billion (+2%, 0% cc), with volume growth contributing 14 percentage points, partly offset by 12 percentage points from generic competition. Pricing had a negative impact of 2 percentage points, and currency had a positive impact of 2 percentage points.

Operating income was USD 10.8 billion (-23%, -24% cc), declining mainly due to higher R&D expenses, including a USD 1.9 billion partial impairment charge of the del-desiran IPR&D asset, and higher other expense.

Net income was USD 7.6 billion (-34%, -35% cc), mainly due to lower operating income, higher interest expense and higher income taxes. EPS was USD 4.01 (-32%, -33% cc).

Core operating income was USD 16.9 billion (-1%, -2% cc), declining mainly due to higher R&D expenses and higher other expense, partly offset by lower SG&A expenses. Core operating income margin was 40.1% of net sales, decreasing 1.1 percentage points (0.8 percentage points in cc).

Core net income was USD 13.0 billion (-4%, -5% cc), mainly due to lower core operating income and higher interest expense. Core EPS was USD 6.85 (-1%, -3% cc), benefiting from the lower weighted average number of shares outstanding.

Free cash flow amounted to USD 14.0 billion (-12%), declining due to lower net cash flows from operating activities.

Q3 priority brands

Underpinning our financial results in the quarter is a continued focus on key growth drivers (ranked in order of contribution to Q3 growth) including:

Kisqali	(USD 1 821 million, +37% cc) continued to grow strongly across all regions, with market share growth in early breast cancer and leadership in metastatic breast cancer.
Kesimpta	(USD 1 484 million, +22% cc) sales showed continued strong momentum globally, driven by increased demand and broad access.
Scemblix	(USD 593 million, +67% cc) sales grew across all regions, with continued strong momentum in the early-line setting in the US, Japan and Germany.
Leqvio	(USD 506 million, +63% cc) sales grew across all regions, with continued uptake in China following NRDL inclusion.
Cosentyx	(USD 1 857 million, +9% cc) sales grew in most markets, driven by the HS and SpA indications. US growth benefited from prior-year revenue deduction adjustments.
Pluvicto	(USD 674 million, +20% cc) sales showed continued strong demand driven by the mAPMR¹ setting, with US and China approvals in mAPMN/S²  in Q3, and ongoing access expansion ex-US.
Zolgensma Group	(USD 404 million, +35% cc) sales grew strongly, reflecting continued launch momentum from Itvisma in the US, Japan and other ex-US countries.
Rhapsido	(USD 101 million) continued to show strong launch uptake in the US, supported by sustained prescription growth and a free drug program facilitating patient access. Ex-US, sales were mainly driven by early launch uptake in Germany and China.
Fabhalta	(USD 237 million, +60% cc) sales grew, with expansion in PNH and renal indications.

¹ Metastatic androgen pathway modulation-resistant prostate cancer (mAPMR), also known as metastatic castration resistant prostate cancer (mCRPC).
^²  Metastatic androgen pathway modulation-naïve or sensitive prostate cancer (mAPMN/S), also known as metastatic hormone-sensitive prostate cancer (mHSPC).

Net sales of the top 20 brands in the third quarter and nine months

	Q3 2026	% change		9M 2026	% change
	USD m	USD	cc	USD m	USD	cc
Cosentyx	1 857	9	9	5 247	8	6
Kisqali	1 821	37	37	5 032	45	44
Kesimpta	1 484	21	22	4 072	27	26
Entresto	1 165	-38	-38	3 651	-44	-45
Pluvicto	674	20	20	1 967	42	41
Jakavi	564	5	5	1 697	9	6
Tafinlar + Mekinist	570	4	4	1 644	-2	-4
Ilaris	591	25	26	1 616	18	17
Scemblix	593	66	67	1 588	78	78
Leqvio	506	64	63	1 438	67	63
ZolgensmaGroup	404	34	35	1 071	16	13
Xolair	331	-25	-25	1 061	-21	-23
SandostatinGroup	311	3	3	900	-2	-4
Lutathera	219	3	3	655	7	6
Fabhalta	237	59	60	631	80	79
ExforgeGroup	183	4	1	577	6	2
Promacta/Revolade	142	-61	-61	505	-64	-65
DiovanGroup	137	-4	-6	447	0	-3
Tasigna	141	-36	-37	438	-53	-54
Piqray/Vijoice	122	36	37	326	8	8
Top 20 brands total	12 052	7	7	34 563	3	1

R&D update – key developments from the third quarter

New approvals

Rhapsido (remibrutinib)	In October, FDA approved Rhapsido as the first treatment for adults with symptomatic dermographism (SD) inadequately controlled by H1 antihistamines, expanding its use beyond chronic spontaneous urticaria (CSU) into chronic inducible urticaria (CIndU). Novartis plans to submit the full RemIND dataset to health authorities globally.
Pluvicto (lutetium Lu177 vipivotide tetraxetan)	FDA and China’s NMPA approved Pluvicto in combination with an androgen receptor pathway inhibitor (ARPI) for patients with PSMA+ metastatic androgen pathway modulation-naive/sensitive (mAPMN/S) prostate cancer¹. Pluvicto is now approved across all stages of PSMA+ metastatic prostate cancer.
Fabhalta (iptacopan)	Japan’s MHLW approved Fabhalta for the treatment of IgA nephropathy (IgAN), making it the first approved treatment for this indication in Japan.   Additionally, FDA granted traditional approval of Fabhalta in IgAN.

¹  Also known as metastatic hormone-sensitive prostate cancer (mHSPC).

Regulatory updates

Cosentyx (secukinumab)	CHMP adopted a positive opinion recommending approval for Cosentyx in polymyalgia rheumatica (PMR), based on positive Phase III REPLENISH data. If approved, Cosentyx will be the first IL-17A inhibitor approved in Europe for PMR.
DAK539 (pelabresib)	Regulatory submission for pelabresib in myelofibrosis was completed in the EU, based on the positive Phase III MANIFEST-2 study, which showed deep and durable disease control, with a safety profile comparable to ruxolitinib alone, including numerically fewer deaths and disease progressions in the pelabresib arm.
KPE179 (del-zota)	Del-zota was granted priority review by FDA for people living with Duchenne muscular dystrophy who have a genetic variant that may be amenable to exon 44 skipping (DMD44). Del-zota previously received FDA Breakthrough Therapy designation.
Leqvio (inclisiran)	FDA updated the Leqvio label to include language recognizing that lowering LDL-C reduces the risk of major adverse cardiovascular events (MACE) in adults at increased cardiovascular risk. This update reflects established evidence from statins and monoclonal antibody PCSK9 inhibitors, supporting LDL-C reduction as a key component of cardiovascular risk management.
Vanrafia (atrasentan)	Regulatory submissions for Vanrafia in IgAN were completed in Japan and China.
KLU156 (ganaplacide + lumefantrine)	Regulatory submission for KLU156 in uncomplicated malaria was completed in the US and received priority review.

Results from ongoing trials and other highlights

LOU064 (remibrutinib)	Positive results from the Phase III REMODEL-1 and -2 trials showed oral remibrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), significantly reducing annualized relapse rate (ARR) versus teriflunomide. Remibrutinib also showed superiority on all key secondary endpoints, including MRI lesion reduction, and a clinically meaningful delay in disability progression. The safety profile was favorable and consistent with remibrutinib in CSU, with no liver safety signal. Data were presented at MSToronto2026 in October.
EWF980 (del-desiran)	In the Phase III HARBOR study, del-desiran did not meet its primary endpoint of video hand opening time (vHOT) versus placebo in myotonic dystrophy type 1 (DM1). Evidence of clinical activity was observed in secondary endpoints and exploratory analyses. Novartis is evaluating the full HARBOR dataset and will engage with health authorities to determine the most appropriate development path. Data will be presented at an upcoming medical congress.
TQJ230 (pelacarsen)	In the Phase III HORIZON trial, pelacarsen did not meet its primary endpoint of reducing the risk of cardiovascular events versus placebo in patients with elevated Lp(a) and established cardiovascular disease (CVD), despite reducing Lp(a) levels in this study population. The findings provide important new evidence on the relationship between Lp(a) lowering and cardiovascular outcomes and may help inform future approaches to cardiovascular risk management. Data will be presented at an upcoming medical congress.
Kisqali (ribociclib)	The six-year follow-up analysis of the Phase III NATALEE trial showed a clinically meaningful overall survival (OS) benefit with Kisqali plus endocrine therapy (ET) versus ET alone in the broadest HR+/HER2- early breast cancer (eBC) population at high risk of recurrence, reducing the risk of death by nearly 20%. Patients had been off Kisqali treatment for a median of 38 months, with clinical benefit continuing to deepen after treatment completion. The safety profile remained consistent with previous analyses. Data were presented at ESMO 2026.
LOU064 (remibrutinib)	Novartis has discontinued the Phase III study of remibrutinib in generalized myasthenia gravis (gMG) following a futility analysis, which indicated the treatment was unlikely to meet its efficacy objectives. No safety concerns were identified, and there is no impact on remibrutinib studies in other indications.
Selected transactions	Novartis completed the acquisition of Myricx Bio, strengthening the oncology pipeline with a new class of antibody-drug conjugates (ADCs), including two lead assets targeting B7-H3 and HER2, as well as a broader payload platform with potential impact across multiple solid tumor settings.   Novartis exercised its exclusive option to acquire full global rights to Sironax’s proprietary Brain Delivery Module (BDM) platform, a next-generation blood-brain barrier crossing technology with the potential to transform the treatment of central nervous system diseases.   Novartis entered into an exclusive global licensing agreement with BoomRay Pharmaceuticals for an undisclosed preclinical radioligand therapy asset, further strengthening its radioligand therapy portfolio.   In October, Novartis entered into a strategic licensing and option agreement with Abogen Biosciences to advance RNA-encoded therapeutics, including an exclusive worldwide license to ABO2203, a novel mRNA-encoded CD19xCD3 T-cell engager with the potential to transform the treatment landscape for autoimmune diseases. The transaction is subject to the completion of customary closing conditions.

Capital structure and net debt

Retaining a good balance between investment in the business, a strong capital structure, and attractive shareholder returns remains a priority.

During the first nine months of 2026, Novartis repurchased 30.9 million shares for USD 4.7 billion on the SIX Swiss Exchange second trading line. These repurchases included 18.8 million shares (USD 2.8 billion) under the up-to USD 10 billion share buyback announced in July 2025 (with up to USD 4.9 billion still to be executed). In addition, 12.1 million shares (USD 1.8 billion) were repurchased to mitigate the anticipated full-year dilution related to participation plans of employees. Further, 2.0 million shares (USD 0.3 billion) were repurchased from employees. During the same period, USD 0.9 billion of equity-based compensation plan expenses were recognized to equity and 13.3 million shares were delivered to employees related to equity-based compensation plans from prior years. As a result, the total number of shares outstanding decreased by 19.6 million compared with December 31, 2025. These treasury share transactions resulted in an equity decrease of USD 4.1 billion and a cash outflow of USD 4.8 billion.

Net debt increased to USD 37.4 billion at September 30, 2026, compared with USD 21.9 billion at December 31, 2025. The increase was mainly due to the free cash flow of USD 14.0 billion being more than offset by the net cash outflow for M&A, intangible assets transactions and other acquisitions of USD 16.7 billion, the USD 9.1 billion annual dividend payment and cash outflows for treasury share transactions of USD 4.8 billion.

As of Q3 2026, the long-term credit rating for the company is Aa3 with Moody’s Ratings and AA- with S&P Global Ratings.

2026 outlook

Barring unforeseen events; growth vs. prior year in cc
Net sales	Expected to grow low single-digit
Core operating income	Expected to be in line to grow low single-digit (from decline low single-digit)

Foreign exchange impact

If late-October exchange rates prevail for the remainder of 2026, the foreign exchange impact for the year would be positive 1 percentage point on net sales and positive 1 percentage point on core operating income. The estimated impact of exchange rates on our results is provided monthly on our website.

2027 Annual General Meeting

Nomination for election to the Board of Directors

The Novartis Board of Directors announced today that it is nominating Rajesh Jha for election to the Board. During a 36-year career at Microsoft, Mr. Jha held a series of senior leadership roles across software engineering, productivity platforms and enterprise technologies, and served on the company’s Senior Leadership Team from 2016 until his retirement. Most recently, he served as Executive Vice President, Experiences + Devices, where he led the product teams for Microsoft 365, Office, Teams, Windows + Devices, and Dynamics, and played a key role in the integration of artificial intelligence across Microsoft’s product portfolio. His extensive experience in technology, AI and large-scale digital platforms would add significantly to the Novartis Board of Directors.

Key figures¹ 

	Q3 2026	Q3 2025	% change			9M 2026	9M 2025	% change
	USD m²	USD m²	USD	cc		USD m²	USD m²	USD	cc
Net sales	14 522	13 909	4	4		42 043	41 196	2	0
Operating income	1 843	4 501	-59	-61		10 828	14 028	-23	-24
As a % of sales	12.7	32.4				25.8	34.1
Net income	1 196	3 930	-70	-71		7 609	11 563	-34	-35
EPS (USD)	0.63	2.04	-69	-70		4.01	5.94	-32	-33
Net cash flows from operating activities	5 503	6 571	-16			15 061	16 880	-11
Non-IFRS measures
Free cash flow	5 111	6 217	-18			14 002	15 941	-12
Core operating income	6 036	5 460	11	10		16 873	16 960	-1	-2
As a % of sales	41.6	39.3				40.1	41.2
Core net income	4 655	4 330	8	6		13 027	13 522	-4	-5
Core EPS (USD)	2.46	2.25	9	8		6.85	6.94	-1	-3

1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 45 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.     2. USD millions unless indicated otherwise.

Detailed financial results accompanying this press release are included in the Condensed Interim Financial Report at the link below:
https://www.novartis.com/sites/novartis_com/files/q3-2026-interim-financial-report-en.pdf

Disclaimer
This communication contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “expected,” “anticipated,” “can,” “will,” “continue,” “ongoing,” “growth,” “launch,” “expanding,” “deliver,” “accelerate,” “guidance,” “outlook,” “priority,” “potential,” “momentum,” “on track,” “pipeline,” “evidence,” “progress,” “emerging,” or similar expressions, or by express or implied discussions regarding: potential new products, potential new indications for existing products, potential product launches or potential future revenues from any such products; or results of ongoing clinical trials; potential future, pending or announced transactions; potential future sales or earnings; strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing; our capital structure. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this communication will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. Neither can there be any guarantee that the expected benefits or synergies from the transactions described in this communication will be achieved in the expected timeframe, or at all. In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; the success of key products, commercial priorities and strategy; the research and development of new products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; our ability to realize the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities; the development or adoption of new technologies, including artificial intelligence, and new business models; the implementation of our new IT projects and systems; potential significant breaches of information security or disruptions of our information technology systems; actual or potential legal proceedings, including regulatory actions or delays or government regulation related to the products and pipeline products described in this communication; safety, quality, data integrity, or manufacturing issues; our performance on and ability to comply with environmental, social and governance measures and requirements; major macroeconomic and geo- and socio-political developments, including the impact of any potential tariffs on our products or the impact of war in certain parts of the world; future global exchange rates; future demand for our products; and other risks and factors referred to in Novartis AG’s most recently filed Form 20-F and in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this communication as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

All product names appearing in italics are trademarks owned by or licensed to Novartis.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

Novartis will conduct a conference call with investors to discuss this news release today at 13:00 Central European time and 8:00 Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Novartis website. A replay will be available after the live webcast by visiting https://www.novartis.com/investors/event-calendar.

Detailed financial results accompanying this press release are included in the Condensed Interim Financial Report at the link below. Additional information is provided on our business and pipeline of selected compounds in late-stage development. A copy of today’s earnings call presentation can be found at https://www.novartis.com/investors/event-calendar.

Important dates
November 18-19, 2026	Meet Novartis Management 2026 (London, UK)
February 3, 2027	Fourth quarter & full year 2026 results
March 5, 2027	Annual General Meeting

# # #

Novartis Media Relations E-mail: media.relations@novartis.com
Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com

Please find full media release in English attached and on the following link:
Media release (PDF)

Further language versions are available through the following links:

German version is available through the following link:
Medienmitteilung (PDF)

• Third quarter 2026 total revenues increased by 21% to US$117.6 million, compared to third quarter 2025, exceeding market expectations
• RUCONEST® revenue increased by 14% to US$93.8 million, compared to third quarter 2025, reflecting demand stabilization and seasonal inventory increase
• Joenja® (leniolisib) revenue increased by 58% to US$23.8 million, compared to third quarter 2025, reflecting strong U.S. and international demand
• Tightened 2026 total revenue guidance to US$380 million – US$390 million from prior US$375 million – US$395 million
• Operating profit increased by 89% to US$29.9 million, compared to third quarter 2025
• Generated US$32.4 million in cash flow from operations in the quarter and US$24.7 million year to date, increasing cash position to US$190.9 million
• Strong progress on Joenja expansion including U.S. pediatric label and launches in Germany and Japan
• Announced positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation and Phase II topline data in broader CVID patient population expected in November 2026
• Pharming to host a conference call today at 13:30 CET (8:30 am EDT)

Leiden, the Netherlands, October 27, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, presents its preliminary (unaudited) financial report for the three months ended September 30, 2026.

Interim Co-Chief Executive Officer Kenneth Lynard commented: “This was a quarter of execution and delivery for Pharming. We set three near-term goals – stabilizing and returning RUCONEST to revenue growth, expanding Joenja (leniolisib)’s reach, and generating Phase II data for leniolisib beyond APDS. We made strong progress on all three in the third quarter, and momentum continues into the fourth quarter. RUCONEST quarterly revenue rose 14% year-over-year to $93.8 million, supported by stabilized U.S. demand with the strongest retention in the high-burden patient segment, and continued new patient and prescribers additions. Joenja revenue grew 58% to $23.8 million with launches in Germany and Japan, higher U.S. uptake, and approval in the U.S. of new doses for children aged 4 to 11 above 27 kg with shipments commencing after quarter end. That performance translated into 21% revenue growth exceeding market expectations, an 89% increase in operating profit, and strong operating cash flow, highlighting our flexibility to invest in our priorities while staying disciplined on capital allocation.

Interim Co-Chief Executive Officer Leverne Marsh added: We are particularly encouraged by the recent positive Phase II results for leniolisib in genetically identifiable primary immunodeficiencies, which support the role of the PI3Kδ pathway in driving immune dysregulation beyond APDS. We look forward to reporting additional data in CVID in November. Together, results from both trials will inform the path toward a potential registrational study in the broader and larger CVID population. If supported by the data, this could represent a significant opportunity for leniolisib, building on the commercial capabilities we have established with Joenja to reach more patients and realize our long-term growth ambition.”

Third quarter highlights

Commercialized assets
RUCONEST marketed for the treatment of acute HAE attacks

RUCONEST revenue in the third quarter of 2026 was US$93.8 million, a 14% increase compared to the third quarter of 2025 and a 30% increase compared to the second quarter of 2026. Revenue for the first nine months of 2026 was US$224.5 million, a 3% decrease compared to the same period in 2025.

RUCONEST revenue in the current quarter compared to the third quarter of 2025 reflects stabilization and continued recovery of U.S. market demand, early seasonal increase in channel inventory at a single U.S. specialty pharmacy customer following significant drawdowns earlier in the year, and the completion of the planned withdrawal from non-U.S. markets.

The overwhelming majority of RUCONEST patients remain on therapy with the active patient base over 90% of year ago levels, with strongest retention in the high-burden patient segment. We continued to add new patients and prescribers, highlighting RUCONEST’s durable market position in high-burden HAE.

Joenja (leniolisib) marketed for the treatment of APDS

Joenja revenue increased to US$23.8 million in the third quarter of 2026, a 58% increase compared to the third quarter of 2025. Revenue for the first nine months of 2026 was US$55.7 million, a 45% increase compared to the same period in 2025.

Year-over-year revenue growth in the current quarter was driven by continued strong growth in the number of U.S. patients on paid therapy, significantly increased international demand – including from launches in Germany and Japan during the quarter and continued penetration in the U.K. – with temporary benefit from ordering patterns in other international markets.

The U.S. market contributed 67% of third quarter revenue, while international contributed 33%.

As of September 30, 2026, 136 patients were on paid therapy in the U.S., representing a 17% increase from the 116 patients at the end of the third quarter of 2025 and an increase of 4 patients during the quarter. Shipments of newly approved Joenja doses for children aged 4 to 11 years in the U.S. commenced in October, following the end of the quarter.

As of September 30, 2026, 75 patients were on paid therapy in international markets – 30 in launch markets and 45 on paid access programs in other international markets.

APDS patient finding

As of September 30, 2026, we have identified 1,056 diagnosed activated PI3Kδ syndrome (APDS) patients of all ages globally, including 304 patients in the U.S. and 390 in core markets outside of the U.S.

Joenja (leniolisib) development
Leniolisib for APDS

As of September 30, 2026, there are 136 APDS patients in either a leniolisib Expanded Access Program (compassionate use) or an ongoing clinical study.

Pediatric label expansion

On September 11, 2026, we announced that the U.S. Food and Drug Administration (FDA) had approved our supplemental New Drug Application (sNDA) for 40 mg and 50 mg twice-daily dosing of Joenja as a treatment for children aged 4 to 11 years weighing at least 27 kg with APDS.

On July 30, 2026, we submitted a separate sNDA seeking approval of lower Joenja doses for pediatric APDS patients aged 4 to 11 years who weigh 13 kg to 27 kg. On September 28, 2026, we announced that the FDA had accepted this sNDA and granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2027.

Japan

On August 13, 2026, we announced the commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 years and older, following its inclusion on the Japan National Health Insurance (NHI) drug price list. With this launch, Japan became the first market where Joenja was commercially available for children aged 4 to 11.

Leniolisib for additional primary immunodeficiencies (PIDs)

Two Phase II clinical trials are evaluating leniolisib for additional primary immunodeficiencies (PIDs) with immune dysregulation, including genetically identifiable PIDs linked to altered PI3Kδ signaling and common variable immunodeficiency (CVID), which represent substantially larger patient populations than APDS. The PI3Kδ pathway is seen as a key driver of immune dysregulation in many PIDs, and we are working towards a single registrational Phase III trial in the broader CVID indication, incorporating patient populations from both studies.

On October 14, 2026, we presented positive topline data from our Phase II trial of leniolisib in genetically identifiable PIDs with immune dysregulation at the 22nd Biennial Meeting of the European Society for Immunodeficiencies (ESID). This is the first clinical data for leniolisib in broader PIDs beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulation. The trial enrolled 13 participants, nine of whom also had a CVID diagnosis. All participants who completed the study elected to continue receiving treatment in a long-term extension study.

The presentation highlighted leniolisib’s favorable safety and tolerability profile, as well as clinical improvements across measures of immune dysregulation. Clinical results included improvements in lymphoproliferative disease, with mean 26.4% spleen volume reduction (SVR) including reductions in nearly all evaluable participants, and reductions in the size of index lesions. Positive trends in lung and liver disease markers were also particularly noteworthy. The safety observations were consistent with the known safety profile of leniolisib, with infections as the most common events observed in study subjects, and no new safety signals identified. Notably, all 12 participants who completed the study elected to enroll in the three-year extension study.

Pharming expects to report Phase II results for leniolisib in CVID patients with immune dysregulation, with or without an identified genetic cause, in November 2026.

The estimated prevalence rate is approximately 7.5 patients per million for genetically identifiable PIDs and approximately 39 patients per million for CVID with immune dysregulation, including overlap between the genetic PID and CVID populations, which are substantially larger than the approximately 1.5 patients per million for APDS.

Napazimone (KL1333) for mitochondrial DNA-driven primary mitochondrial disease

Napazimone (KL1333) is being evaluated in the pivotal FALCON clinical trial in adult patients with mtDNA-driven mitochondrial disease, and has the potential to become the first standard of care in this setting.

Over 50 clinical sites in the trial are actively recruiting, with significant expansion achieved in the U.S. We expect approximately 145 of the planned 180 subjects to be enrolled in FALCON by the end of 2026. We now expect enrollment to be completed in the first half of 2027. Topline results from the pivotal FALCON study are expected approximately one year after the completion of enrollment.

Organizational updates

On September 29, 2026, we announced that the Board of Directors and Fabrice Chouraqui had mutually agreed that Mr. Chouraqui would step down as Chief Executive Officer and Executive Director, with immediate effect. To ensure continuity of leadership, the Board of Directors appointed Mrs. Leverne Marsh, Chief Commercial Officer, and Mr. Kenneth Lynard, Chief Financial Officer, as Interim Co-CEOs.

Pharming’s strategy, pipeline and commitment to patients remain unchanged. Focus remains on executing the strategic priorities and advancing the next phase of growth.
Financial Summary

Consolidated Statement of Income	3Q 2026	3Q 2025	9M 2026	9M 2025
Amounts in US$m except per share data
Total Revenues	117.6	97.3	280.2	269.6
Cost of sales	(15.4)	(7.1)	(36.6)	(24.4)
Gross profit	102.2	90.2	243.7	245.2
Other income	2.3	0.1	4.1	2.3
Research and development	(29.6)	(23.4)	(87.4)	(68.2)
General and administrative	(15.6)	(17.0)	(45.7)	(59.9)
Marketing and sales	(29.5)	(34.1)	(88.3)	(99.7)
Other Operating Costs	(74.6)	(74.5)	(221.5)	(227.9)
Operating profit (loss)	29.9	15.8	26.3	19.6
Finance result (net) and share of result in associates	1.4	(3.1)	3.2	(11.6)
Profit (loss) before tax	31.2	12.7	29.5	8.0
Income tax credit (expense)	(8.8)	(5.2)	(10.7)	(10.8)
Profit (loss) for the period	22.4	7.5	18.9	(2.8)
Earnings per share
Basic, attributable to equity holders of the parent (US$)	0.032	0.011	0.027	(0.004)
Diluted, attributable to equity holders of the parent (US$)	0.030	0.010	0.025	(0.004)

Segment information – Revenues	3Q 2026	3Q 2025	9M 2026	9M 2025
Amounts in US$m
Revenue – RUCONEST (US)	94.0	81.1	224.2	227.4
Revenue – RUCONEST (EU and RoW)	(0.1)	1.1	0.3	3.9
Total Revenues – RUCONEST	93.8	82.2	224.5	231.2
Revenue – Joenja (US)	15.9	13.4	42.8	34.6
Revenue – Joenja (EU and RoW)	7.9	1.7	12.9	3.7
Total Revenues – Joenja	23.8	15.1	55.7	38.4
Total Revenues – US	109.8	94.5	267.0	262.0
Total Revenues – EU and RoW	7.7	2.7	13.2	7.6
Total Revenues	117.6	97.3	280.2	269.6

Consolidated Balance Sheet	September 30, 2026	December 31, 2025
Amounts in US$m
Cash and cash equivalents, restricted cash and marketable securities	190.9	181.1
Current assets	322.4	299.5
Total assets	496.6	500.0
Current liabilities	100.0	115.8
Shareholders’ equity	291.2	277.1

Figures may not add up due to rounding.

Financial highlights

Third quarter 2026

For the third quarter of 2026, total revenues increased by US$20.3 million, or 21%, to US$117.6 million, compared to US$97.3 million in the third quarter of 2025. RUCONEST revenues amounted to US$93.8 million, a 14% increase compared to the third quarter of 2025. This increase in RUCONEST revenues was primarily driven by a volume increase in the U.S. Joenja revenues amounted to US$23.8 million in the third quarter of 2026, a 58% increase compared to the third quarter of 2025. This increase in Joenja revenues was primarily driven by an increase in volume.

Gross profit increased by US$12.0 million or 13%, to US$102.2 million, compared to US$90.2 million in the third quarter of 2025, mainly due to the increase in revenues and partially offset by manufacturing-related impairments of inventory (US$5.1 million).

The operating profit increased 89% and amounted to US$29.9 million compared to US$15.8 million in the third quarter of 2025. Excluding US$5.1 million in one-time manufacturing-related impairments of inventory, adjusted operating profit¹ in the third quarter 2026 amounted to US$35.0 million. Excluding US$0.2 million of non-recurring Abliva acquisition-related expenses, adjusted operating profit in the third quarter 2025 amounted to US$16.0 million. The improved operating result was primarily driven by an increase in revenues and other income from government grants supporting research and development activities.

The finance result (net) and share of result in associates amounted to a gain of US$1.4 million compared to a loss of US$3.1 million in the third quarter of 2025. This improvement was mainly driven by favorable EUR/USD exchange rate movements, resulting in a foreign currency gain of US$2.6 million in 2026, compared to a loss of US$0.4 million in the third quarter of 2025.

The Company had a net profit of US$22.4 million, compared to a net profit of US$7.5 million in the third quarter of 2025. This increase was primarily driven by higher revenues and a favorable change in the net finance result.

Cash generated from operations amounted to US$32.4 million, broadly in line with US$32.0 million in the third quarter of 2025. Cash and cash equivalents, restricted cash and marketable securities increased by US$31.4 million from US$159.5 million at the end of the second quarter of 2026 to US$190.9 million at the end of the third quarter of 2026. This increase was primarily driven by net profit, partially offset by unfavorable working capital movements, including an increase in trade and other receivables.

¹ Adjusted Operating Profit is a non-IFRS measure used by management to assess underlying operating performance and provides additional insight into the Company’s core operating profitability. It excludes certain non-core items.

Nine months 2026

Total revenues increased 4% during the first nine months of 2026 to US$280.2 million, compared to US$269.6 million during the first nine months of 2025. Total RUCONEST revenues were 3% lower at US$224.5 million, compared to revenues of US$231.2 million for the first nine months of 2025. The decrease in RUCONEST revenues was primarily driven by a decrease in volume. Joenja revenues amounted to US$55.7 million in the first nine months of 2026, a 45% increase compared to the first nine months of 2025. This increase in Joenja revenues was primarily driven by an increase in volume.

Gross profit decreased by US$1.5 million, or 1%, to US$243.7 million, compared to US$245.2 million in the first nine months of 2025, mainly due to manufacturing-related impairments of inventory (US$10.0 million) partially offset by the increase in revenues.

The operating profit amounted to US$26.3 million compared to an operating profit of US$19.6 million in the first nine months of 2025. Excluding US$10.0 million in one-time manufacturing-related impairments of inventory and US$1.7 million in expenses associated with the closure of the production-support site in Évry, France, adjusted operating profit in the first nine months of 2026 amounted to US$38.0 million. Excluding US$10.1 million of non-recurring Abliva acquisition-related expenses, adjusted operating profit in the first nine months of 2025 amounted to US$29.7 million. The improved operating result was primarily driven by an increase in revenues and lower operating expenses, partially offset by manufacturing-related impairments of inventories in 2026.

The finance result (net) and share of result in associates amounted to a gain of US$3.2 million compared to a loss of US$11.6 million in the first nine months of 2025. This improvement was mainly driven by favorable EUR/USD exchange rate movements, resulting in a foreign currency gain of US$7.9 million in the first nine months of 2026, compared to a loss of US$5.0 million in the first nine months of 2025.

The Company had a net profit of US$18.9 million, compared to a net loss of US$2.8 million in the first nine months of 2025. This increase was primarily driven by higher revenues, lower operating expenses and a favorable change in the net finance result.

Cash generated from operations amounted to US$24.7 million, compared to US$44.0 million in the first nine months of 2025. Cash and cash equivalents, restricted cash and marketable securities increased by US$9.8 million from US$181.1 million at the end of 2025 to US$190.9 million at the end of the third quarter of 2026. This increase was primarily driven by net profit, partially offset by US$12.3 million settlement of the lease liability following the early termination of the DSP facility lease at Pivot Park in Oss, the Netherlands, in the first quarter of 2026.

Outlook/Summary

For 2026, the Company anticipates:

• Total revenues between US$380.0 million and US$390.0 million (1% to 4% growth).
• Total operating expenses between US$310.0 million and US$315.0 million (0% to 1% growth), including approximately US$35 million incremental R&D investment to advance the pipeline and US$9 million structural G&A cost reductions based on the plan announced in October 2025.
• RUCONEST revenue stabilization and return to growth during second half of 2026, and significant and accelerating annual Joenja U.S. and ex-U.S. growth.
• Commercial launches for leniolisib for APDS patients 12 years of age or older and for pediatrics in key global markets.
• Top-line data readouts for the two ongoing leniolisib Phase II clinical trials in PIDs with immune dysregulation, including CVID, to expand the asset’s addressable patient population.
• Continued progress in enrollment of the pivotal FALCON clinical study for napazimone (KL1333) in mitochondrial DNA-driven primary mitochondrial diseases, with completion of enrollment by the first half of 2027.
• Enhancing capital efficiency to drive growth and build a leading global rare disease company.
• Continued focus on potential acquisitions and in-licensing of clinical stage opportunities in rare diseases. Financing, if required, would come via a combination of our strong balance sheet and access to capital markets.

No further specific financial guidance for 2026 is provided.

Trademarks
Joenja® and RUCONEST® are registered trademarks owned by or licensed to Pharming Group N.V. or its affiliates.

Additional information
Presentation

The conference call presentation is available on the Pharming.com website from 07:30 CET today.

Conference Call

The conference call will begin at 13:30 CET/08:30 EDT on Tuesday, October 27. A transcript will be made available on the Pharming.com website in the days following the call.

Please note, the Company will only take questions from dial-in attendees.

Webcast Link:

https://edge.media-server.com/mmc/p/nnjperkk

Conference call dial-in details:

https://register-conf.media-server.com/register/BI6feabfc862ab4ba1bc7e6386d00414a3

Additional information on how to register for the conference call/webcast can be found on the Pharming.com website.

For further public information, contact:

Pharming
Michael Levitan, VP Investor Relations & Capital Markets
T: +1 (908) 705 1696
E: investor@pharming.com

Saskia Mehring, Head of Corporate Communications
T: +31 6 28 32 60 41
E: media.relations@pharming.com

Media Relations
Julia Deutsch (Lyra Strategic Advisory on behalf of Pharming)
E: JDeutsch@lyraadvisory.com

Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)
T: +31 6 53 81 64 27

About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biotechnology company that develops and commercializes innovative medicines for people living with rare immune and genetic diseases.

We combine specialized scientific, medical, regulatory and commercial expertise to advance a focused portfolio of approved medicines and development programs that address significant unmet medical needs. Guided by insights from patients and the wider rare disease community, we are dedicated to delivering innovative therapies for some of the most challenging rare diseases.

Pharming is headquartered in Leiden, the Netherlands, with operations in the United States and Europe.

For more information, visit www.pharming.com and find us on LinkedIn.

Auditor’s involvement
The Condensed Consolidated Interim Financial Statements have not been audited by the Company’s statutory auditor.

Forward-looking Statements

This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as “aim”, “ambition”, “anticipate”, “believe”, “could”, “estimate”, “expect”, “goals”, “intend”, “may”, “milestones”, “objectives”, “outlook”, “plan”, “probably”, “project”, “risks”, “schedule”, “see”, “should”, “target”, “will” and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming’s preclinical studies and clinical trials of its product candidates, Pharming’s clinical and commercial prospects, and Pharming’s expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming’s clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming’s 2025 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming’s actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.

Inside Information

This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Pharming Group N.V.

Condensed Consolidated Interim Financial Statements in US Dollars (unaudited)

For the period ended September 30, 2026

• Condensed consolidated interim statement of income
• Condensed consolidated interim statement of comprehensive income
• Condensed consolidated interim balance sheet
• Condensed consolidated interim statement of changes in equity
• Condensed consolidated interim statement of cash flows

CONDENSED CONSOLIDATED INTERIM STATEMENT OF INCOME
For the period ended September 30
Amounts in US$ ‘000	9M 2026	9M 2025
Revenues	280,217	269,602
Costs of sales	(36,553)	(24,366)
Gross profit	243,664	245,236
Other income	4,097	2,303
Research and development	(87,389)	(68,221)
General and administrative	(45,738)	(59,945)
Marketing and sales	(88,345)	(99,746)
Other Operating Costs	(221,472)	(227,911)
Operating profit (loss)	26,289	19,628
Fair value gain (loss) on revaluation	—	—
Other finance income	11,152	1,748
Other finance expenses	(8,144)	(13,048)
Finance result, net	3,008	(11,300)
Share of net profits (loss) in associates using the equity method	233	(279)
Profit (loss) before tax	29,530	8,049
Income tax credit (expense)	(10,677)	(10,838)
Profit (loss) for the period	18,853	(2,790)
Attributable to:
Equity holders of the parent	18,853	(2,477)
Non-controlling interests	—	(313)
Earnings per share
Basic, attributable to equity holders of the parent (US$)	0.027	(0.004)
Diluted, attributable to equity holders of the parent (US$)	0.025	(0.004)

CONDENSED CONSOLIDATED INTERIM STATEMENT OF COMPREHENSIVE INCOME
For the period ended September 30
Amounts in US$ ‘000	9M 2026	9M 2025
Profit (loss) for the period	18,853	(2,790)
Currency translation differences	(11,258)	26,092
Items that may be subsequently reclassified to profit or loss	(11,258)	26,092
Fair value remeasurement investments	—	—
Items that shall not be subsequently reclassified to profit or loss	—	—
Other comprehensive income (loss), net of tax	(11,258)	26,092
Total comprehensive income (loss) for the period	7,595	23,303
Attributable to:
Equity holders of the parent	7,595	23,616
Non-controlling interests	—	(313)

CONDENSED CONSOLIDATED INTERIM BALANCE SHEET
Amounts in US$ ‘000	September 30, 2026	December 31, 2025
Non-current assets
Intangible assets	125,667	135,538
Property, plant and equipment	6,165	7,233
Right-of-use assets	13,335	16,738
Long-term prepayments	91	94
Deferred tax assets	19,051	31,017
Investment accounted for using the equity method	2,109	1,944
Investment in debt instruments designated as at FVTPL	6,485	6,703
Restricted cash	1,355	1,227
Total non-current assets	174,258	200,495
Current assets
Inventories	57,988	64,902
Trade and other receivables	74,831	54,704
Restricted cash	—	761
Marketable securities	—	33,796
Cash and cash equivalents	189,560	145,305
Total current assets	322,379	299,469
Total assets	496,637	499,963
Equity
Share capital	8,086	8,009
Share premium	520,912	513,257
Other reserves	17,518	28,819
Accumulated deficit	(255,277)	(272,983)
Shareholders’ equity	291,239	277,102
Non-current liabilities
Convertible bonds	94,344	92,719
Lease liabilities	11,102	14,351
Total non-current liabilities	105,446	107,070
Current liabilities
Convertible bonds	5,584	5,336
Provisions	816	1,187
Trade and other payables	90,069	105,899
Lease liabilities	3,483	3,369
Total current liabilities	99,952	115,791
Total equity and liabilities	496,637	499,963

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CHANGES IN EQUITY
For the period ended September 30
Attributable to owners of the parent
Amounts in US$ ‘000	Share capital	Share premium	Other reserves	Accumulated deficit	Total	Non-controlling interests	Total equity
Balance at January 1, 2025	7,769	488,990	(209)	(275,489)	221,061	—	221,061
Profit (loss) for the period	—	—	—	(2,477)	(2,477)	(313)	(2,790)
Reserves	—	—	—	—	—	—	—
Other comprehensive income (loss) for the period	—	—	26,092	—	26,092	—	26,092
Total comprehensive income (loss) for the period	—	—	26,092	(2,477)	23,616	(313)	23,303
Other reserves	—	—	(32)	32	—	—	—
Income tax benefit from excess tax deductions related to share-based payments	—	—	—	807	807	—	807
Share-based compensation	—	—	—	9,256	9,256	—	9,256
Options exercised / LTIP shares issued	184	18,727	—	(8,320)	10,592	—	10,592
Acquisition of a subsidiary	—	—	—	—	—	7,741	7,741
Acquisition of non-controlling interests	—	—	—	(687)	(687)	(7,428)	(8,115)
Total transactions with owners, recognized directly in equity	184	18,727	(32)	1,087	19,967	313	20,280
Balance at September 30, 2025	7,953	507,717	25,852	(276,878)	264,644	—	264,644
Balance at January 1, 2026	8,009	513,257	28,819	(272,983)	277,102	—	277,102
Profit (loss) for the period	—	—	—	18,853	18,853	—	18,853
Reserves	—	—	—	—	—	—	—
Other comprehensive income (loss) for the period	—	—	(11,258)	—	(11,258)	—	(11,258)
Total comprehensive income (loss) for the period	—	—	(11,258)	18,853	7,595	—	7,595
Other reserves	—	—	(43)	34	(9)	—	(9)
Income tax benefit from excess tax deductions related to share-based payments	—	—	—	(629)	(629)	—	(629)
Share-based compensation	—	—	—	8,353	8,353	—	8,353
Options exercised / LTIP shares issued	77	7,655	—	(8,905)	(1,173)	—	(1,173)
Total transactions with owners, recognized directly in equity	77	7,655	(43)	(1,147)	6,542	—	6,542
Balance at September 30, 2026	8,086	520,912	17,518	(255,277)	291,239	—	291,239

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CASH FLOWS
For the period ended September 30
Amounts in $’000	9M 2026	9M 2025
Profit (loss) before tax	29,530	8,049
Adjustments to reconcile net profit (loss) to net cash used in operating activities:
Depreciation, amortization, impairment of non-current assets	8,745	8,010
Equity settled share based payments	8,353	9,256
Loss (gain) on disposal of leases	(2)	(9)
Impairments of inventories¹	11,777	2,183
Other finance income	(11,152)	(1,748)
Other finance expenses	8,088	12,837
Share of net result in associates using the equity method	(233)	279
Operating cash flows before changes in working capital	55,106	38,857
Changes in working capital:
Inventories¹	(5,372)	(5,686)
Provisions	(371)	—
Trade and other receivables	(14,801)	11,453
Payables and other current liabilities	(4,797)	4,138
Restricted cash	569	(1,018)
Total changes in working capital	(24,772)	8,887
Interest received	2,991	1,723
Income taxes received (paid)	(8,660)	(5,466)
Net cash flows generated from (used in) operating activities	24,665	44,001
Capital expenditure for property, plant and equipment	(601)	(480)
Investment intangible assets	—	(6)
Investment in associates using the equity method	—	(731)
Purchases of marketable securities	(102,646)	—
Proceeds from sale of marketable securities	18,124	84,990
Acquisition of a subsidiary, net of cash acquired	—	(57,476)
Net cash flows generated from (used in) investing activities	(85,123)	26,297
Payment of lease liabilities	(14,803)	(2,877)
Interests on lease liabilities	(349)	(848)
Interests on convertible bonds	(2,614)	(2,506)
Settlement of share based compensation awards	5,703	14,564
Acquisition of non-controlling interests	—	(7,876)
Net cash flows generated from (used in) financing activities	(12,063)	457
Increase (decrease) of cash	(72,521)	70,755
Exchange rate effects	(1,020)	6,672
Effect of reclassification of money market funds to cash and cash equivalents2	117,796	—
Cash and cash equivalents at the beginning of the period	145,305	54,944
Total cash and cash equivalents at September 30	189,560	132,370

---

¹ Comparative presentation updated for consistency.
² Money market funds are classified as cash equivalents from April 1, 2026

Attachment

• Pharming Group reports third quarter 2026 results_EN_27OCT2026